Prerpints.org logo
Preprint
Review

COVID-19: From Emergence to Endemicity - A Comprehensive Review

Altmetrics

Downloads

390

Views

267

Comments

0

Submitted:

08 July 2023

Posted:

11 July 2023

You are already at the latest version

Alerts
Abstract
Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), later renamed Coronavirus Disease 2019 (COVID-19) was first identified in Wuhan, China, in early December 2019. Initially, the China office of the World Health Organization was informed of numerous cases of pneumonia of unidentified etiology in Wuhan, Hubei Province on December 31, 2019. This would subsequently result in a global pandemic with over 76 million confirmed cases of COVID-19 and 6.9 million deaths reported to the WHO. We have analyzed most of the data published since the beginning of the pandemic to compile this comprehensive review of SARS-CoV-2. We look at the core ideas, such as the etiology, epidemiology, pathogenesis, clinical symptoms, diagnostics, histopathologic findings, consequences, therapies, and vaccines. We have also included the long-term effects and myths associated with some therapeutics of COVID-19. This study comprehensively assesses of the SARS-CoV-2 virology, vaccines, medicines, and significant variants identified during the pandemic. Our review article is intended to provide medical practitioners with a better understanding of the fundamental sciences, clinical treatment, and prevention of COVID-19. As of June 2023, this paper contains the most recent data made accessible.
Keywords: 
Subject: Medicine and Pharmacology  -   Epidemiology and Infectious Diseases
  • Introduction
Coronavirus Disease 2019 (COVID-19) was first identified in December 2019 and has since spread to nearly every corner of the globe (1). The pathogen causing COVID-19 infection is a novel coronavirus that is structurally related to the virus that causes severe acute respiratory syndrome (SARS). Because of its global spread, the World Health Organization (WHO) declared it a pandemic on March 12, 2020 (1). COVID-19 has had a devastating impact, claiming millions of lives. Even though vaccines were produced and delivered at an unprecedented rate, the virus has mutated and evolved over time, posing a threat to survival.
The effects were felt differently in different parts of the world, and even the most developed countries with robust healthcare systems and protocols were not immune (2). To stem the spread of the disease, large-scale lockdowns had been implemented in several parts of the world, along with preventive measures such as the widespread use of facial masks and the universal practice of hand hygiene. The economic burden imposed by COVID-19 was insurmountable in the form of healthcare costs, including vaccines, nationwide lockdowns, and industrial shutdowns, resulting in financial recession in most of the world (3). COVID-19 has been found to affect almost all the organs in the body, causing a wide range of symptoms and posing a diagnostic challenge in several cases (4).
Several vaccines and drugs have been developed to control infection spread and disease severity because of extensive research and development around the world. Despite significant progress in mitigating the effects of COVID-19, as of March 31, 2023, the disease continues to spread globally, with the end game nowhere in sight (5).
  • Etiology
Coronaviruses are spherical, enveloped, positive-sense, single-stranded RNA viruses found in humans, other mammals, and birds (6). The envelope contains spike glycoproteins giving the crown-like appearance under an electron microscope. Coronaviruses are divided into four main subgroups: alpha, beta, gamma, and delta. Alpha and beta coronaviruses likely originate from bats and rodents whereas the gamma and delta variants likely come from the avian species (7).
Coronavirus was first identified in the humans in mid-1960s. Since then a total of seven coronaviruses known to infect humans have been identified (Figure 1), namely, 229E and NL63 (alpha coronavirus), OC43 and HKU1 (beta coronavirus) causing milder, self-limiting, upper respiratory symptoms; SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus), and SARS-CoV-2 are beta coronaviruses known to be virulent and capable of widespread infections with clinical manifestations of varying severity (8).
SARS-CoV-2 is a novel coronavirus belonging to the beta subgroup. The virus closely resembles two bat-derived coronaviruses, bat-SL-CoVZC45, and bat-SL-CoVZXC21 (9). The virus is heat sensitive, although highly stable at 4℃ and with a wide range of pH at room temperature (3-10) but also susceptible to standard disinfection methods (10).
The origin of the virus remains unclear to date. Isolating closely resembling SARS-CoV-2 from horseshoe (Rhinolophus) bats of Yunnan caves in mainland China was a strong possibility however this theory was deemed unlikely given the geographical distance between the caves and Wuhan province, where the first case was identified (11). Viruses appearing closely related to SARS-CoV-2 have also been identified in pangolins from China, Cambodia, Japan, and Thailand (12). A possibility of spillover from bats to humans in Wuhan markets where animals, carriers of SARS-CoV-2, are sold alive for food was also postulated but later noted that the virus was not identified in these animals. Finally, widespread speculation exists that the virus escaped from the Wuhan Institute of Virology, which researches SARS-related viruses. However, two different lineages of SARS-CoV-2 were simultaneously identified at different locations of Wuhan wildlife markets, leading to a likely natural origin for the virus with a yet-to-be-identified wild-caught or farmed animal (13).
Cross-species transmission is perhaps one of the most vital aspects of SARS-CoV-2 ecology as viral transmission from humans to animals has been documented in farmed minks, dogs, cats, and even wild animals including lions and tigers in zoos (14–16). Upon animal infection, the human virus evolves and adapts to the new host. These recombinant human and animal coronaviruses may generate further novel viruses with a concern for spillover in humans, with partial or absent immunity, leading to a potential pandemic in the future (17).
  • COVID-19 variants and their characteristics
COVID-19 has caused a devastating effect on the world's population, leading to millions of deaths. Since the beginning of the pandemic, SARS-CoV-2 has evolved, mutated, and produced variants with variable transmissibility and virulence, also altering the performance of vaccines (18), diagnostic tools, therapeutic medicines, and other preventive measures.
SARS-CoV-2 being an RNA virus is prone to genetic evolution while adapting to their new human hosts with the development of mutations over time, resulting in the emergence of multiple variants (19). The SARS-CoV-2 variants (Table 1) that emerged from the novel strain include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) (20). The timeline of the emergence of these variants is illustrated in Figure 2.
SARS-CoV-2 variants were designated with Greek alphabet letters according to their characteristics and classified by the WHO as follows (21).
  • Variants Being Monitored (VBM)
Variants having genetic changes suspected to affect virus characteristics with an indication that there may be a future risk associated with them. Alpha (B.1.1.7 and Q lineages), Beta (B.1.351 and descendent lineages), Gamma (P.1 and descendent lineages), Delta (B.1.617.2 and AY lineages), Epsilon (B.1.427, B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Unnamed (1.617.3), Omicron (B.1.1.529 and descendent lineages), Zeta (P.2), and Mu (B.1.621, B.1.621.1) are the variants in this category.
  • Variant of Concern (VOC)
Variants with increased transmissibility, increased virulence or decrease in effectiveness to available diagnostics, vaccines, and therapeutics. Omicron (B.1.1.529, BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages) are listed as VOC.
  • Variants of Interest (VOI)
SARS-CoV-2 variants with genetic changes that are predicted or known to affect virus characteristics and have significant community transmissibility with emerging risk to global public health. There are currently no variants that are designated as VOI.
  • Variants of High Consequence (VOHC)
Variants with clear evidence of reduced effectiveness to medical countermeasures or preventative measures compared to the previously circulating variants. Currently, there are no variants designated as VOHC.
    • Alpha variant
The alpha variant was initially detected in the United Kingdom at the end of 2020, spreading rapidly in France, and soon became the dominant strain in March and June 2021 (22). CDC classified it as a VOC once the variant was detected in the US. It was reported to be 43% to 82% more transmissible than pre-existing variants of SARS-CoV-2 (23). In mid-April in the US, alpha comprised 66% of cases before delta emerged.
The most common symptoms reported were chills, headache, muscle aches, sore throat, fever, cough, and loss of appetite. However, loss of taste and smell were reported less commonly. The alpha variant was associated with increased disease severity, hospitalizations, and mortality compared to previous strains (24). Vaccines were effective in preventing severe disease and hospitalization in Alpha cases (25).
    • Beta variant
The CDC classified Beta (B.1.351), alongside Alpha, as a variant of concern in December 2020 after it was discovered in South Africa in May 2020 (26). Analysis of the spike substitutions revealed significant immune evasion, which was supported by reductions in neutralizing antibody titers in serum from individuals who had previously been exposed to Beta-variant infections (27). A significant infection surge in South Africa was noted due to the beta variant leading to increased hospitalizations and mortality during the second wave. Moreover, it appears that vaccines are less successful at protecting against the beta variant (28). This variant is more contagious and produces more severe illness than the novel SARS-CoV-2 (29).
Infections from the beta variant were associated with a 24% greater risk of severe illness, a 49% higher risk of critical illness, and a 57% higher risk of COVID-19-related death when compared to infections with the alpha variant. Acute-care admissions rose during the beta wave however intensive care unit (ICU)hospitalizations and deaths quadrupled, with this variant having a disproportionately more significant impact on critical illnesses and COVID-19-related deaths (30).
    • Delta variant
Delta variant was first identified in India in December 2020 (31), leading to a dramatic increase in COVID-19 cases and massive epidemics with record-breaking cases and deaths. Due to its strong transmissibility and ability to lead to an epidemic, it was classified as a VOC (20). The delta variant caused more than twice as many infections as the previous variants (32). It was estimated to have been 80 to 90% more transmissible than the alpha variant. Researchers reported that the viral load was 1000 times higher in people infected with the delta variant compared to people infected with prior variants of SARS-CoV-2 and this could be related to its increased transmissibility (33).
The symptoms caused by the delta variant do not differ from its predecessors. Delta caused more severe diseases than other variants. It has been observed that patients infected with this variant had higher hospitalization, ICU admissions, adverse events, and death compared to previous variants (34). Several cases of mucormycosis, candidiasis, and aspergillosis were reported in India during the Delta variant outbreak.
Vaccination was highly effective against severe illnesses, hospitalizations, and deaths from the delta variant (25). Infections were detected even in fully vaccinated people. Since vaccinated patients with infections could spread the virus, CDC recommended layered prevention strategies for both vaccinated and unvaccinated people. In addition to being vaccinated, the public was advised to practice hand washing, wearing masks, and maintaining physical distance.
    • Delta AY.4.2
On June 11, 2021, Public Health England started covering the AY.1 sub-lineage of the delta variant, which carries a second K417N mutation in the spike protein. The "Delta Plus" is another name for this AY.1 variation. AY.4.2 had two mutations to its spike protein, AY145H, and A222V but were not located where they would inhibit vaccine or treatment. It was thought to be 10-20% more transmissible than the Delta variant. No increased hospitalizations or death were noted. According to the CDC, vaccines are still quite successful in keeping people out of hospitals and preventing mortality against delta and its sub-variants (35).
The WHO and other organizations have put forth strategies to stop the establishment and spread of these novel variations. These include genomic surveillance at the local level, better access to anti-SARS-CoV-2 vaccines, widespread availability of face masks, quicker identification of infected patients, and implementation of appropriate containment strategies. To stop the creation of new SARS-CoV-2 variations, it is crucial to put these techniques into practice.
    • Omicron variant
This is the most recent variant designated as a variant of concern by the WHO on November 26, 2021 (36). Omicron has over 50 mutations in its genome, rendering it the most mutated SARS-CoV-2 variant. Omicron has been discovered to have an effective (instantaneous) reproduction number of 3.19 (95% CI 2.82–3.61) times higher than the Delta variant. This variant was found soon after in Austria, Australia, Belgium, Canada, Czech Republic, Denmark, France, Germany, Italy, Netherlands, and the United Kingdom, with the majority of the cases being linked to travel (36).
The Omicron variant, a subtype of the Pango lineage B.1.1.529, has continuously undergone a sequence of unheard-of mutations and evolved to exhibit a wide range of characteristics (37). Between 11 and 14 November 2021, variant B.1.1.529 was first discovered in Botswana, which was followed by South Africa (21). It is a variant of concern because of its great transmissibility and low susceptibility to being neutralized by antibodies produced either by prior viral exposure or vaccination. The Omicron variant's high infectivity and transmissibility properties are attributed to significant spike (S) protein mutations. This variant's enhanced transmissibility is due to the substitutions N501Y and Q498R having a greater affinity for the ACE-2 receptors, one of the receptor binding domain alterations (38).
Omicron is less severe than other variants, with a hospitalization risk that is 15% to 80% lower than the delta variant (39). Omicron reproduces 70 times quicker than delta in human bronchi while reproducing ten times slower in human lung tissue, according to findings from ex vivo experiments. This explains why patients with infections from Omicron variants experience less severe disease (40). It spawned a variety of sub-variants in 2022, including BA.5, BQ.1, and BQ.1.1 (41). By January 2023, most infections in the United States were being caused by a new Omicron subvariant known as XBB.1.5. Up to February 2023, Omicron and its sub-variants have been the most common SARS CoV-2 strains in the United States (41).
    • A brief history of the Origins
The SARS-CoV-2 pandemic started three years ago on December 1, 2019, but its exact origins are still unknown and are a subject of intense scientific and political dispute (42–44). Although the virus was believed to have most likely spread from a marine food market in Wuhan, Hubei Province, China, there is currently no convincing evidence to support this and controversies still exist (45). An outbreak of severe pneumonia with an unknown organism was reported to the World Health Organization (WHO) on December 31, 2019, in Wuhan, Hubei Province, China, a city with a population of approximately 11 million (46). About 66% of the initial 41 patients admitted to the hospital with an unidentified pneumonia infection by 2 January 2020 had direct exposure to the Huanan Wholesale Seafood Market (hereafter, "Huanan market") (47).
An international team of scientists assembled by the WHO visited Wuhan, China in January 2021, the location of the first discovery of the virus that causes COVID-19. As part of phase one research, the team evaluated data on when and how the virus may have evolved in collaboration with Chinese researchers (48). The combined international team evaluated the possibility of many possible routes for the introduction of the virus and issued several suggestions for each route as mentioned below (49).
The likelihood of each potential pathway was evaluated by the joint team using the following criteria: a. Introduction by a direct zoonotic spillover was considered a possible route; b. Introduction through an intermediate host was regarded as a probable-to-very likely pathway; c. Introduction through products used in the cold and food chain was thought to be a plausible method; d. Introduction through a laboratory incident was thought to be a very unlikely method (49).
    • Introduction via intermediate host followed by zoonotic transmission
Explanation of hypothesis: SARS-CoV-2 spreads within the intermediate host (also known as the spillover host) after being transmitted from an animal reservoir to an animal host, and then it spreads to humans. Without (top row of animals) or with virus adaptation (bottom row of animals), the virus can pass through an intermediate host (45).
    • Direct zoonotic spread
Explanation of hypothesis: The transmission of SARS-CoV-2 (or a closely related progenitor virus) from an animal reservoir host to a human in this instance was followed by direct person-to-person transmission with (top row of human icons) or without (bottom row) the necessity for the virus to adapt to humans (49).
    • Introduction through the cold/food chain
Food-chain transmission might represent spillage through an intermediary host or direct zoonotic transmission. In the meantime, cold chain products might be a means of human transmission. This would include both introductions and instances of food contamination. This paragraph focuses on cold/food chain goods and their packaging as a potential SARS-CoV-2 entry point. Thus, it’s crucial to make the distinction between cold chain product contamination causing additional outbreaks in 2020 and the possibility that cold chain will serve as the entry point for the pandemic's origin in 2019 (49).
    • Introduction through a laboratory incident
Explanation of hypothesis: A laboratory incident results in the introduction of SARS-CoV-2, reflecting an accidental infection from staff during the laboratory activity involving the relevant viruses. They did not consider the theories of deliberate release or intentional bioengineering of SARS-CoV-2 for release, the latter of which has been debunked by other researchers after genome analysis (49).
After the well-publicized trip two years ago, the WHO halted its phase-two ambitions. According to Nature, WHO has discreetly abandoned the second stage of its highly anticipated scientific investigation into the origins of the COVID-19 pandemic citing persistent difficulties with attempting to carry out crucial investigations in China (9). According to Maria Van Kerkhove, an epidemiologist at the WHO in Geneva, Switzerland, phased work was planned by the WHO, but "that plan has changed," she claimed. Chinese officials disapproved of the WHO's objectives, particularly the proposal to investigate lab breaches. According to Zhao Lijian, the spokesperson for China's foreign ministry, not all member nations concurred with the WHO plan, and the second phase shouldn't focus on possibilities that the mission report had previously considered highly implausible (48).
On 02/26/23, The Wall Street Journal added to the discussion by reporting that the U.S. Department of Energy has changed its position regarding the cause of COVID-19 (43). It has been determined that the epidemic was most likely caused by a laboratory leak in Wuhan, China, although with "low confidence" (50). Low confidence, according to the federal government, refers to "limited, questionable, fragmented, or that strong analytical conclusion cannot be formed from the evidence". Moreover, there is currently no consensus within the American intelligence community regarding the origin of SARS-CoV-2 (44).
    • Economic Burden of COVID-19
The COVID-19 pandemic created not only a health crisis but also an economic burden throughout the world. While quantifying the total economic impact, cost of direct medical costs, loss of productivity as well as costs due to non-pharmaceutical interventions like lockdown or mitigation strategies needs to be included (51). At the beginning of the pandemic, economic data was scarce. Still, due to the extent of economic impact, several studies have been published from different regions providing some insights on costs (52–55).
  • Lockdown Cost
During the initial phase of the pandemic, various countries implemented mitigation strategies of varying intensity and timing. A cost-benefit analysis of the lockdown in the United Kingdom (Miles et al. 2021) with a best-case scenario also saw a 68 billion pound loss and in the worst scenario a 547 billion loss based on different gross domestic product loss assumptions and QALY (quality-adjusted life year) loss assumptions (56).
  • Pre-Vaccination Cost
The pandemic has had a major impact on contact-intensive sectors like health and social care, hospitality, recreation, retail and wholesale, and transportation. Rand Corporation ran several scenarios to find out how vaccination availability will affect the GDP of various countries' economies. In one scenario, when the world economy allowed activity without effective vaccination, it would cause contact–intensive service sectors to lose about $3.4 trillion globally in GDP terms annually. This corresponded to about 3.7% of the global GDP and 2.2% of the US GDP (56).
  • Direct Healthcare Cost
USA: In the early days of the pandemic, a study used the Monte Carlo simulation model to estimate potential healthcare costs in the US population. An estimated median direct medical cost was $3,045 during the course of infection, and total direct medical costs over the course of the pandemic ranged from $163.4 billion if 20% of the US population got infected to $654.0 billion if 80% of the US population was infected (57).
Worldwide: The cost of COVID-19 treatment had a disastrous economic outcome for many families in low and medium-economic countries. A study from Greece estimated cost per non-ICU patient and ICU patient were 8,852 euros and 24,167 euros, respectively (53). Cost analysis of 3254 patients with suspected or confirmed COVID-19 hospitalized in a large public hospital in São Paulo, Brazil between March 30 and June 30, 2020, showed an average cost of US $12,637.42 (54). A study reviewed 745 COVID-19 patients treated in Iran, with an estimated mean total cost of $8813.15 which accounted for 60% of the per capita (58). Another study evaluated the medical records of 400 patients admitted to an Iranian hospital for COVID-19 treatment with an estimated mean cost of treatment at $1,434 (55). Another study from Turkey analyzed invoices of non-ICU and ICU patients and found the mean cost for non-ICU patients was $881.75 ± 667.31 (range: $45.07 - $7584.81), whereas the mean cost for ICU patients was $2924 ± 2347.14 (range: $223.01- $9681.88) (51,59).
  • Testing
Cost analysis of 598,502 COVID-19 samples collected for tracing and diagnosis in Addis Ababa, Ethiopia showed the unit because of sample collection per COVID-19 positive individual was USD 11.63 and the unit because of COVID-19 positive test through cardiac testing was USD (60).
  • Indirect cost (Loss of revenue and productivity)
During the initial stages of the pandemic, due to the lack of adequate testing and PPE, elective procedures were canceled leading to a loss of revenue to the healthcare system. A retrospective study compared the total revenue generated between the pre-COVID-19 era and the COVID-19 era and found a 55.7% decline in revenue generated by the Orthopedic division of a single large tertiary hospital in Pakistan (61).
  • Vaccination cost (Development, production, and administration)
Estimating the total cost of COVID-19 vaccination is challenging due to the various types of vaccinations and different deployment strategies used by various countries. As a part of Operation Warp Speed (OWS), the United States government invested around USD 18 billion for the development and clinical trials for a total of 6 vaccine candidates from Moderna, AstraZeneca/Oxford, Johnson and Johnson, and Sanofi/GSK. BioNTech has received $445 million in funds from the German government to develop COVID-19 vaccine development. The United States purchased 200 million doses of the Moderna vaccine at $30 per person, and 400 million doses of the Pfizer-BioNTech vaccine at $39 per person (62).
A study by Ghana's Ministry of Health’s technical working group for health technology assessment using WHO–UNICEF COVID-19 vaccine introduction and deployment casting (CVIC) estimated cost of $20.9–$26.2 per person to complete the primary vaccination schedule, which included the cost of the vaccine (63).
    • Age, Gender, and Racial Disparities
Age is considered a significant predictor of COVID-19 severity and mortality (64,65). According to the CDC data, age is the strongest risk factor for severe COVID-19 outcomes, with the risk of death increasing exponentially with age (66). Compared with individuals aged 18-29 years, the risk of death is 25 times higher in those aged 50-64 years, 60 times higher in those aged 65-74 years, 140 times higher in those aged 75-84 years, and 340 times higher in those aged 85 years or older (67).
Recent studies indicate that individuals who identify as male are at a higher risk of mortality from COVID-19, possibly due to androgen-mediated regulation of the transmembrane protease serine 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE-2), which could facilitate the entry and replication of SARS-CoV2 (64,68,69). Other potential explanations for this gender disparity include differences in immune and inflammatory reactions and clotting and bleeding tendencies (69).
COVID-19 infections and mortality risk were found to be higher among black and minority ethnic groups compared to white individuals. Despite identifying differences in socioeconomic determinants, and comorbidities such as cardiovascular disease and diabetes as contributing factors, they do not fully account for the observed disparities (64,70,71). Further investigation is warranted to elucidate the underlying factors.
    • COVID-19 Pathophysiology
Coronaviruses are spherical, enveloped, positive-sense, single-stranded RNA viruses found in humans, other mammals, and birds (6). Six species are known to affect humans, of which four viruses (229E, OC43, NL63, and HKU1) predominantly lead to common cold symptoms, mostly in immunocompetent individuals (72). The other two strains are severe acute respiratory syndrome coronavirus (SARS-CoV-1) responsible for the 2002-2003 SARS-CoV pandemic, and the Middle East respiratory syndrome coronavirus (MERS-CoV) found first in the Arabian peninsula in 2012 (73). The third strain is the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) leading to the global outbreak of coronavirus disease of 2019 (COVID-19).
SARS-CoV-2 has a diameter ranging from 60-140 nm, with distinctive spikes giving the appearance of a solar corona (Figure 3). The size of the SARS-CoV-2 genome is about 30 kb. Bats are likely a natural reservoir for SARS-CoV-2, with a hypothesis that humans are infected via an intermediate host such as the pangolin (73).
The four main structural proteins responsible for the virion assembly and suppression of the host immune response include the envelope (E) protein, membrane (M) protein, nucleocapsid (N), and the spike (S) protein (74). The spike protein plays a significant role in the host entry of SARS-CoV-2. They consist of two subunits: the S1 subunit, binding to the host ACE-2 receptor, and the S2 subunit, mediating the membrane fusion (75).
ACE-2 receptors are expressed abundantly on the type II alveolar epithelial cells, and also by the myocardial cells, enterocytes from the ileum, upper esophagus, urothelial cells of the bladder, and proximal tubular cells of the kidney. Upon binding to host ACE-2 through the Receptor Binding Domain (RBD), the S1 subunit undergoes cleavage propelled by the host membrane protein TMPRSS2. This activates the S2 subunit enabling the fusion of viral and host lipid bilayers resulting in the release of the viral ribonucleoprotein into the host cell leading to viral replication (76).
SARS-CoV-2 predominantly affects the respiratory and vascular systems thus making COVID-19 a disease mostly of the pulmonary and vascular systems. Three phases based on the severity of the disease have been postulated: early infection phase (stage 1) comprising of viral replication with mild symptoms; pulmonary phase (stage 2) leading to predominantly respiratory symptoms from the host immune response; and finally the hyperinflammation phase (stage 3) leading to widespread inflammation and tissue injury (77) (Figure 4).
    • Early infection phase (Stage 1)
During this stage, the viral RNA replicates upon entry into the pulmonary parenchyma leading to mild constitutional symptoms consisting of fever, headaches, myalgias, dry cough, and sore throat. Patients limited to this stage of COVID-19 have excellent prognosis and recovery.
    • Pulmonary phase (Stage 2)
In this stage, the continued viral replication and pulmonary inflammation can lead to the development of viral pneumonia, and, in severe cases, hypoxia needing hospitalization.
    • Hyperinflammation phase (Stage 3)
About 30% of the patients from the early infection and pulmonary phase progress to this stage (78). The hallmark of this stage is significant elevations in inflammatory cytokines and biomarkers IL-2, IL-6, IL-7, macrophage inflammatory protein 1-α, granulocyte colony-stimulating factor, tumor necrosis factor-α (TNFα)-, ferritin, C-reactive protein, and D-dimer. In severe disease, high levels of cytokines, IL-6, and TNF-α are released leading to a phenomenon called “cytokine storm” leading to widespread inflammation (79). Multiple mechanisms have been proposed for the increased vascular permeability with the resultant pulmonary edema. First, there is direct viral invasion and disruption of the endothelial cell membranes leading to endotheliitis. Second, there is widespread vascular thrombosis with microthrombi and the potential to lead to disseminated intravascular coagulation (DIC). Thirdly, the dysregulated RAAS allows increased viral attachment to ACE-2 receptors and increased vascular permeability due to the activation of the kinin-kallikrein system, leading to the release of bradykinin, a potent vasodilator. Lastly, the surge in the inflammatory response leads to enhanced contraction of epithelial cells leading to cellular edema and disruptions of the tight intercellular junctions. The role of the virus binding to Toll-Like Receptor (TLR) has been proposed in the mediation of lung inflammation and fibrosis (78,80–82).
Systemic widespread inflammation is evident with the release of Troponin and N-terminal pro-B-type natriuretic peptide can also be elevated, in some cases, leading to viral myocarditis (83). Secondary hemophagocytic lymphohistiocytosis has been reported in advanced diseases (84). Progressive disease can lead to ARDS, shock, and cardiopulmonary collapse.
    • Histopathology
Autopsy studies of patients deceased from severe COVID-19 have provided valuable insights into the myriad of histopathological findings that have been described in detail below according to the organ systems.
  • Respiratory system
Macroscopic findings include pulmonary congestion with areas of hemorrhagic necrosis (85). In an autopsy study of 68 consecutive patients with COVID-19, diffuse alveolar damage was present in 87% of patients. Airway inflammation, type 2 pneumocyte (AT2 cell) hyperplasia, and the presence of hyaline membranes in the alveolar areas were noted in both short-term and long-term disease, however, AT2 cell hyperplasia and interstitial fibroblastic proliferation were typically seen in patients with longer duration of illness (Figure 5). Extensive pulmonary thromboembolism was noted in 42% of the lungs (86). In another study (Borczuk et al. 2020), an autopsy of 10 COVID-19 patients showed the presence of pulmonary thromboembolism in 89% of the lungs studied, abundant with both platelet-predominant and fibrin-predominant thrombi in the vasculature of the alveolar septa (87).
  • Gastrointestinal system
    • Liver
Hepatic steatosis appears to be the predominant finding, with focal necrosis in the periportal region (88). Biliary plugs in the small-sized bile ducts have been observed. Nodular proliferation and periportal inflammation with lymphocytic infiltration are also seen (85).
    • Gastrointestinal tract
Endoscopic studies have shown no significant damage to the mucosa of the stomach, duodenum, and rectum. Infiltrating plasma cells, lymphocytes were noted abundantly in the lamina propria of the stomach, duodenum, and rectum. Interestingly, viral proteins stain positively in the cytoplasm of the gastric, duodenal, and rectal glandular epithelial cells, excluding the esophageal epithelium (89).
  • Urinary and Reproductive System
    • Kidneys
Microscopic changes range from diffuse proximal tubular injury with the loss of brush-border epithelium, vacuolar degeneration (non-isometric in most cases) to necrosis as described in an autopsy study of 26 patients with COVID-19. Electron microscopic (EM) examination showed tubular epithelium and podocytes with viral particles bearing distinctive spikes (90).
  • Testes
In a post-mortem study of testes in 11 male patients deceased from COVID-19 infection, all were noted to show interstitial edema and congestion, tubular basal membrane thickening, strong expression of vascular cell adhesion molecules in the blood vessels, and diminished number of Leydig and Sertoli cells with associated decreased spermatogenesis. EM showed four cases with viral particles in the cytoplasm of Sertoli and Leydig cells, spermatids, fibroblasts, endothelium, and epithelial cells of the rete testis (91).
  • Nervous System
    • Brain
Autopsy study to determine the neuropathological findings in 18 patients revealed the hypoxic-ischemic injury in the cerebral and cerebellar regions in all the patients by microscopic exam. No thrombi or evidence of vasculitis was noted. No abnormalities were noted in the olfactory bulbs or tracts. Immunohistochemical analysis was negative for cytoplasmic viral staining (92).
  • Cardiovascular System
    • Heart
Endomyocardial biopsies of five patients with COVID-19 infection showed myocarditis with necrosis of the myocytes along with granulation tissue and fibrosis along the periphery of necrosis as noticed after an infarction. Immunohistochemical analysis showed significant intramyocardial inflammation (93).
  • Skin
HIstological findings of COVID-19 viral exanthem varied depending on the stage of the illness. Early stages reveal diffuse telangiectasias of small blood vessels, nests of Langerhans cells within the epidermis, and perivascular dermatitis along with dense lymphocytic infiltration. Later stages of infection showed intravascular microthrombi in the small dermal vessels (94).
  • Organ System Manifestations
SARS-CoV-2 has been associated with widespread disease involving all organ systems. The most devastating effects are seen in the lungs; however, other vital organs are also affected causing a variety of manifestations. Figure 6 depicts the various organ manifestations.
Cutaneous manifestations: Various cutaneous manifestations have been reported from different parts of the world. Most reported presentations include petechia, purpura, ecchymosis, maculopapular rash, COVID-19 digits with ischemia, vesicular eruptions, and chilblain-like rash/lesions (95–98).
Some of the common presentations include COVID toes which present as erythematous to purplish lesions over toes and fingers, usually self-resolving (96), with some cases progressing to digital ischemia which is thought to be due to thrombosis and complement deposition, a type 3 delayed hypersensitivity reaction (98). Livedoid pattern rash presents as skin mottling with reticular discoloration on the trunk, and extremities (96). Urticarial presentation is likely IgE-mediated type 1 hypersensitivity immune response to viral antigens/drug haptens (95,96,98). Vesicular eruptions were initially thought to be occurring due to immune response to viral antigens with central umbilication seen similar to varicella infection (96), but were later on, found to be due to co-infection/reactivation with varicella virus (98).
Cardiac manifestations: Various cardiac presentations are seen in COVID-19 patients including myocarditis, cardiomyopathy, heart failure, myocardial ischemia/infarction (7.2%), arrhythmias (18.7%), and shock (8.7%), and arterial or venous thromboembolism (99–101).
Mechanisms of injury are considered to be due to the direct viral invasion of cardiomyocytes or vascular endothelium, systemic inflammation, and cytokine storm causing myocardial injury, supply-demand mismatch due to hypoxemia, and vascular injury causing coagulopathy (98,100). Interstitial fibrosis in the myocardium is caused by the suppression of mothers against decapentaplegic (SMAD) pathway activation by tumor growth factor beta (TGF-b) signaling in COVID-19 infection. Patients with COVID-19 are reported to have a lower survival rate when associated with higher NT-proBNP levels (>88.64 pg/ml) (98).
Hematological manifestations: Different hematological manifestations reported worldwide include thrombocytopenia, increased D-dimer, prolonged aPTT (activated partial thromboplastin), prolonged PT (prothrombin time), low fibrinogen levels, increased serum ferritin, increased lactate dehydrogenase, arterial and venous thrombosis, elevated IL-6 (Interleukin-6), and elevated CRP (C-reactive protein) (102,103). Sporadic case reports of inflammation related to COVID-19 infection, leading to hemophagocytic lymphohistiocytosis (HLH) have been reported (104). Increased COVID-19-related complications and in-hospital mortality are reportedly noted in patients with higher D-dimer levels (102). Disseminated intravascular coagulation (DIC) has also been reported (105).
Mechanisms of injury are viral entry through adhesion to ACE-2 receptors on endothelial cells, viral replication leading to inflammatory cell infiltration, endothelial apoptosis, and microvascular prothrombotic events. Development of acute procoagulant response to COVID-19 infection due to the high concentration of pro-inflammatory cytokines and chemokines lead to elevated levels of factor VIII, von Willebrand, and fibrinogen which in turn increases the risk of thrombosis (102).
Renal manifestations: Diverse renal manifestations reported worldwide include acute tubular necrosis (ATN), collapsing focal segmental glomerulosclerosis, albuminuria, hematuria, electrolyte derangements (98), minimal change disease, crescentic glomerulonephritis, thrombotic thrombocytopenic purpura (TTP), atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, renal vein thrombosis, diffuse proliferative glomerulonephritis, acute kidney injury (106–110).
Mechanism of injury noted from autopsy studies revealed evidence of viral infection in innate monocytes, macrophages, NK (natural killer) cells, evidence of viral replication in renal parenchymal cells which was thought to cause tissue damage in the form of ATN (acute tubular necrosis), and glomerulosclerosis (111). Other suggested mechanisms include hypoxia, hypoperfusion of kidneys causing ATN, immune complex deposition of viral particles in the kidneys (109), and induction of a proinflammatory state (98).
Pulmonary Manifestations: Pulmonary embolism, pneumothorax, ARDS (acute respiratory distress syndrome), and pneumonia are the well-known reported presentations during acute infection (103,112). Sporadic case of the secondary bacterial process along with COVID-19 infection causing cavitary lung lesion (113) has been reported. Pneumothorax due to barotrauma from ventilation as well as spontaneous pneumothorax due to damage to the alveolar wall has been reported with a median duration of nine days since the start of symptoms, with a mortality rate of 36% (103,114). Spontaneous pneumomediastinum in a non-ventilated patient has also been reported (115). In an autopsy study, it was shown that massive PE (pulmonary embolism) can occur in initially asymptomatic COVID-19 patients (103,116). In an intensive care unit, COVID-19 patients compared to influenza patients had a three times higher incidence of PE (103,117). The mortality rate in COVID-19 patients is increased with coexistent PE (103,118).
Gastrointestinal manifestations: About 5-50% of patients with COVID-19 infection develop gastrointestinal symptoms such as diarrhea, nausea, vomiting, anorexia, and abdominal pain (119). In 5% of patients, gastrointestinal symptoms precede respiratory symptoms, and a high index of suspicion is required for a timely diagnosis in these patients (120). The ACE-2 receptors are highly expressed in the stratified epithelium of the esophagus, stomach, small intestine, and colon. The mechanisms of gastrointestinal injury in patients with COVID-19 infection include direct infection of the gastrointestinal cells by SARS-CoV-2, cytokine storm, and gastrointestinal damage caused by lung infection by an effect known as “gut-lung axis” in which the damage to the respiratory tract affects the digestive tract via immune regulation (89,121–125).
In rare instances, patients with COVID-19 infection develop ischemic gastrointestinal complications which can be fatal. In a systematic review of 31 patients (Keshavarz et al. 2021), 29% presented with arterial mesenteric thromboembolism, 19.3% with portal venous thrombosis, 64.5% required laparotomy with bowel resection and overall mortality of 38.7% (126). Examination of the small bowel with mesenteric thrombosis revealed prominent endothelium, direct viral invasion of endothelial cells, and diffuse endothelial swelling with mononuclear cell infiltration (124). Patients with severe COVID-19 infection and receiving inotropic agents can develop nonocclusive colonic ischemia due to severe vasoconstriction and reduced mesenteric blood flow (127).
Hepatic manifestations: A systematic analysis of 11 studies with 2,542 patients showed increased AST and/or ALT (25%), and bilirubin (3%) in patients with COVID-19 infection (128). The mechanisms of liver injury in patients with COVID-19 infection are direct cytopathic damage by SARS-COV-2 binding to cholangiocytes expressing ACE-2, cytokine storm, Systemic Inflammatory Response Syndrome (SIRS) induced cholestasis, ischemia hypoxia reperfusion injury, and drug-induced liver injury (119,125,129,130).
Ischemic hepatitis manifests with a rapid rise in serum aminotransferases and may be secondary to septic shock, COVID-19-related myocarditis, and ventilator complications (131). Liver biopsies of patients who died of complications of COVID-19 demonstrated congestion and centrilobular ischemic necrosis in 78% and 40% of cases respectively (132). Patients with severe COVID-19 infection can develop secondary sclerosing cholangitis of critically ill patients (SSC-CIP) because of malperfusion, hypoxia, and recurrent inflammatory stimuli on the biliary epithelium (133).
Neuropsychological manifestations: The various neurological manifestations of COVID-19 infection including cerebrovascular disease, encephalopathy, damage from the immune response, neurodegenerative and demyelinating disorders, seizures, headaches and dizziness, and mental disorders.
Cerebrovascular disease includes ischemic stroke, intracranial hemorrhage, and cerebral venous thrombosis.
Ischemic stroke - The incidence of ischemic stroke in patients with COVID-19 infection is 5-6.92% and predominantly seen in men with a median age of 63 (134–136). Ischemic strokes have been reported in younger patients (age <50) without cardiovascular risk factors prior to the onset of COVID-19 symptoms, and with systemic thrombosis in a quarter of these patients (137–139).
Intracranial hemorrhage (ICH) - ICH is reported in 2.66% of patients with COVID-19. ICH is suspected to be due to vascular endothelial damage and cerebral microhemorrhages more commonly seen in the brainstem (140,141).
Cerebral venous thrombosis (CVT) - This is a rare neurological manifestation secondary to the hypercoagulable state caused by COVID-19 infection and low molecular weight heparin is recommended as the first line treatment (142,143).
Encephalopathy from various etiologies has been listed below.
Hypertensive encephalopathy - ACE-2 receptors are occupied by the viral receptors and the chronic depletion of these receptors increases the risk of angiotensin II (Ang II) dependent hypertension (144). This leads to disruption of the blood-brain barrier, cerebral hyperperfusion, and hypertensive encephalopathy (145).
Hypoxic-ischemic encephalopathy (HIE) due to global hypoperfusion.
Hepatic encephalopathy (HE) in the setting of co-existent liver disease.
Uremic encephalopathy is seen in the setting of acute or chronic renal failure.
Nervous system damage is caused by abnormal immune and inflammatory reactions.
Acute Necrotizing Encephalopathy (ANE) - The cytokine storm in severe COVID-19 infection can result in disruption of the blood-brain barrier and brain necrosis evidenced by bilateral hemorrhagic rim-enhancing lesions in the thalamus (146–148).
Acute Disseminated Encephalomyelitis (ADEM) - Inflammatory response resulting in central nervous system (CNS) demyelination and is rarely reported in adults.
Myelitis - Autoimmune response mainly manifests as acute transverse myelitis. Autoimmune encephalitis - Brain inflammation results in symptoms such as fever, headache, vomiting, seizures, and impaired sensation.
Guillain-Barre syndrome and variants such as Miller Fisher syndrome (MFS) - GBS in COVID-19 is more prevalent in the elderly and males. Patients experience symptoms of COVID-19 for 5-14 days before the onset of paresthesia, lower limb, and facial weakness (149).
Myalgia and myositis - Noted following COVID-19 vaccination (150).
Neurodegenerative and demyelinating disorders - There is no evidence of acceleration of Multiple Sclerosis (MS), Alzheimer's disease, and Parkinson’s disease (PD), in patients with COVID-19 infection (151).
Seizures - Few patients develop seizures due to hypoxia, severe inflammatory state, metabolic derangements, and COVID-19-induced brain damage lowering the seizure threshold (152–154).
Headache and dizziness - It is one of the most common neurological symptoms of COVID-19 infection and occurred in 6-25% and 8-9% of patients, respectively (155).
Mental disorders - The incidence of anxiety, depression, and post-traumatic stress disorder after COVID-19 infection is 17.39-34.7%, 28.5%, and 96.2% respectively (134,156). Due to social isolation and other risk factors, there is an increase in mood disorders, drug abuse, and suicidal tendencies (157,158).
SARS-CoV-2 spreads to the nervous system via the olfactory route through the cribriform plate, the trans-synaptic route via retrograde axonal transport from the peripheral nerves, the leukocytic route via migration of viral particles across the blood-brain barrier, and hematogenous route. The mechanisms causing neurological damage in COVID-19 infection are direct viral binding to the neurons and glial cells, damage to the blood-brain barrier and endothelial system, cytokine storm, effects of hypoxia, post-infectious autoimmune effects via the cellular immunity and autoantibodies, and coagulation disorders (140,159).
Chemosensory loss: In a systematic review of 22 studies, the frequency of COVID-19-associated anosmia, hyposmia, ageusia, and dysgeusia was 55%, 40%, 41%, and 31% respectively (160). The smell and taste disorders last for about 10 days in patients with mild infection and complete resolution is reported in 89% of patients after 4 weeks (161).
The olfactory neuroepithelium comprises olfactory sensory neurons, sustentacular cells, microvillar cells, Bowman glands, and basal cells (162). The airborne chemicals are detected by the olfactory receptors and impulses are transmitted to the olfactory bulb, where the second-order neurons send projections to the primary olfactory cortex in the temporal lobe (163). It is suspected that SARS-CoV-2 infection causes anosmia by damaging the sustentacular cells which are essential for the maintenance and normal function of olfactory cilia and long-lasting anosmia in a small number of patients is due to extensive destruction of the sensory epithelium (164).
The epithelial taste receptors arise from the basal layer of the taste bud and are embedded in the tongue epithelium, palate, and pharynx. The taste cells are connected to the gustatory centers via the cranial nerves VII, IX, and X. Neuropilin-1 (NRP-1) expressed in gustatory nerve fibers and the inflammatory cytokine storm are suspected to play a role in the loss of taste sensation (163).
  • Ocular manifestations:
Ocular surface and cornea - Conjunctivitis is the most common manifestation with a prevalence of about 7% and can manifest early or late (after 10-13 days) (165). There are rare case reports of keratitis, pseudomembranous keratoconjunctivitis, conjunctival follicular reaction, episcleritis, hemorrhagic and pseudo-hemorrhagic conjunctivitis (166,167).
Eyelid manifestations include blepharitis, eyelid edema, eyelid dermatitis, and meibomian orifice abnormalities (168).
Retinal manifestations are secondary to the expression of ACE-2 receptors in the retina and thromboembolic complications. The retinal vascular manifestations include (i) Central retinal vein occlusion, associated with impaired vision while some are asymptomatic. Fundus examination of these patients demonstrated retinal hemorrhages, pan-retinal fern-like whitening, macular edema, and dilated and tortuous vessels, (ii) Central retinal artery occlusion (iii) Acute macular neuro retinopathy (iv) Paracentral acute middle radiculopathy (v) Vitritis, and (vi) Acute retinal necrosis (168–171).
Choroid and uvea - Chorioretinitis is suspected to be due to the inflammatory effect of COVID-19 infection.
Neuro-ophthalmic manifestations include optic neuritis, Miller-Fisher syndrome, and cranial nerve palsy (168).
Vision loss is associated with cerebrovascular accidents.
Orbital manifestations - Rhino-orbital cerebral mucormycosis is the most common orbital manifestation and is the consequence of an impaired immune system, use of corticosteroids, and underlying conditions such as diabetes and renal failure (172,173). Orbital cellulitis is also reported in some patients.
    • COVID-19-associated Endocrinopathies
The COVID-19 pandemic, which has caused catastrophic mortality and morbidity, is still having a significant negative impact on global healthcare systems. It becomes more and more evident that this novel respiratory virus's effects go beyond the respiratory system as time passes and our knowledge of it deepens. TMPRSS2 protein is necessary to gain cellular entry through the ACE-2 receptor. Many endocrine organs exhibit high levels of expression of ACE-2 and TMPRSS2. This has led to a lot of curiosity about how COVID-19 affects the endocrine system, along with several case reports of thyroid and pituitary disruption in these patients. Further, as effective vaccines become more widely available and mortality declines, attention is shifting more and more to the long-term impacts of COVID-19 on patients' health. To inform us of proper research and effective management, this review provides an overview of the data examining the implications of COVID-19 on each endocrine axis.
The wide clinical expression spectrum and multisystem organ failure of COVID-19 and SARS have been linked to both direct injury (caused by virus infection of target cells) and indirect injury (caused by abnormal immune-inflammatory responses to the virus and likely involving the coagulation, cytokine, and the complement systems).
Numerous organs participate in COVID-19, which is pathophysiologically related to an extensive expression of angiotensin-converting enzyme 2 (ACE-2), the receptor that allows SARS-CoV-2 to infect cells, widespread endothelial injury, and a changed immune response.
Additionally, the consequences of COVID-19 go beyond the respiratory system and can last for a long time, with about 10% of patients continuing to experience symptoms weeks after the initial infection. Therefore, we must enhance our understanding of how COVID-19 affects normal physiological function.
    • Thyroid:
In general, thyroid problems are not linked to the severity of COVID-19, nor are they linked to mortality or susceptibility (174). Abnormal thyroid function tests, on the other hand, were often detected in hospitalized COVID-19 patients. These abnormal thyroid function tests were characterized by low thyroid-stimulating hormone (TSH) levels and free thyroxine (fT4). 7% of COVID-19 patients who were hospitalized were found to have non-thyroidal sickness syndrome (NTIS), which is defined by low levels of free triiodothyronine (fT3), high levels of reverse T3, low or normal levels of TSH, and low levels of free thyroxine (fT4) (175). Low levels of fT3 at the time of admission were linked to worsening clinical conditions (176), increased disease severity, and death (177,178). According to Chen et al. 2021, the risk ratio for mortality in COVID-19 individuals with NTIS of 11.64 [95% confidence interval (CI) 4.88–27.78] (177). This was compared to patients who did not have NTIS. Even though both symptomatic and asymptomatic cases of subacute thyroiditis (SAT) due to SARS-CoV-2 infection were recorded, symptomatic SAT due to COVID-19 was an extremely unusual outcome. The SAT that was linked to COVID-19 was very comparable to the traditional SAT, and there was no increase in the frequency of SAT that was recorded during the pandemic. The information that is now available shows that thyroid function tests return to normal once recovery has taken place and that SARS-CoV-2 does not have any long-term influence on thyroid functioning (179).
In general, COVID-19 patients, especially those in the ICU, have a high prevalence of thyroid dysfunction, which is likely an indicator of NTIS. Even though NTIS is linked to mortality, thyroid tests typically return to normal after symptoms subside. COVID-19 individuals with preexisting thyroid issues should be treated following the guidelines for addressing such conditions.
    • Pituitary:
Pituitary disorders are uncommon, making obtaining data on the COVID-19 course in such patients difficult. However, hypopituitarism does not appear to affect COVID-19 results. COVID-19 may be linked to new-onset hypopituitarism via pituitary apoplexy (PA) and hypophysitis.
PA is a clinical and surgical emergency syndrome that is caused by a rapid hemorrhage and blood infarction of the pituitary gland, usually inside a pituitary macroadenoma. It is an acute condition that requires immediate medical attention. Patients often report experiencing abrupt onset and severe headaches, visual abnormalities, and ocular palsy as their primary symptoms (180). These symptoms are caused by the tumor's hemorrhagic and necrotic mass crushing the surrounding optic structures and extending into the cavernous area.
Since SARS-CoV-2 can produce thrombocytopenia, coagulopathy, and platelet dysfunction and has neural tissue tropism owing to ACE-2 expression in cerebral vascular endothelium, COVID-19 could be a possible precipitating risk factor for pituitary apoplexy. This is because COVID-19 has been shown to cause apoptosis of the pituitary gland (181).
As electrolyte imbalances, in general, are seen most frequently in hospitalized patients, hyponatremia has been reported anywhere from 20 to 60% of patients who have had COVID-19. The pathophysiology of hyponatremia in COVID-19 is not well known; however, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and hypovolemia are contributing factors. Even while hypernatremia is less uncommon compared to hyponatremia (5%), it is noticed in COVID-19 patients, particularly in the ICU, and associated with an unfavorable outcome (182).
Based on the above evidence, COVID-19-related prothrombotic and endothelial systemic disease may be triggering risk factors for pituitary apoplexy, particularly in individuals afflicted by pituitary adenomas. Therefore, in both specialist pituitary tumor centers and general medical settings, there must be a greater awareness of this consequence, particularly in patients who are prone to developing it (macroadenoma on dopaminergic medications, anticoagulant treatment).
Patients with COVID-19 who report new-onset headaches and/or neuro-ophthalmological symptoms should be tested at the pituitary gland level (pituitary apoplexy, hypophysitis). Because hyponatremia is so frequent in hospitalized COVID-19 patients, it is essential to check their blood salt levels regularly (183).
    • Adrenal:
COVID-19 has been linked to cases of newly developed primary adrenal insufficiency (AI). Bilateral adrenal hemorrhagic or non-hemorrhagic infarction have been found in these patients, despite there being no obvious infarction or thrombi in the adrenal glands documented in postmortem studies (88). Nearly a quarter of patients with moderate to severe COVID-19 had evidence of acute adrenal infarction on their first chest computed tomography scans, with 88% of these cases being bilateral. Patients with adrenal infarction were more likely to be admitted to the ICU, stay in the hospital longer, and survive, but there was no data on biochemical/clinical hypocortisolism (184).
COVID-19 did not exhibit critical illness-related corticosteroid insufficiency (CIRCI), which is a compromised hypothalamic-pituitary axis (stress) response during critical illness. Instead, the scant evidence we have, suggests that severe cases of COVID-19 are associated with significantly higher cortisol levels in patients compared to those with milder illnesses (185). Similarly, within 48 hours of admission, COVID-19 patients had greater blood cortisol concentrations compared to non-COVID-19 controls, and this was associated with a decreased likelihood of survival (186). However, glucocorticoids, especially dexamethasone, help severely or critically sick COVID-19 patients, probably because of their anti-inflammatory effects.
Histopathological investigations have been the primary source of information regarding the potential effects of COVID-19 on the adrenal glands at this time. The human adrenal cortex contains TMPRSS2 and ACE2. Thus, both animal and human studies have demonstrated SARS-CoV-2 expression and replication in the adrenal glands (187).
Chronic insufficient cortisol production from several causes characterizes AI. Patients with primary AI (PAI), primarily Addison disease (AD), and secondary adrenal insufficiency (SAI) should be regarded as at-risk for being impacted by COVID-19, as indicated in a recent statement made by the European Society of Endocrinology. Adrenal crisis exacerbations have been linked to an increased risk of infection for two reasons: first, because of the increased risk of infections reported in AI patients overall (188), likely due to their inefficient innate immune response, and second, because of the increased mortality rate observed facing respiratory infections (189).
Overall, our knowledge is limited as to how COVID-19 affects the adrenal gland, how the adrenal gland responds to COVID-19, and how COVID-19 progresses in people with adrenal diseases. However, the patients who were examined at arrival and found to have hypercortisolemia rather than CIRCI were not re-evaluated later during their hospital stay, which might have resulted in different outcomes. Currently, many studies are looking at the effects of long COVID, including hypocortisolism post-COVID-19.
    • Reproductive:
Since the beginning of the pandemic, researchers have known that male sex is associated with increased COVID-19 severity and mortality but not susceptibility, highlighting the role of sex in COVID-19 outcomes. Overall, males have a 1.4-fold higher chance of dying of COVID-19 than women (190), but postmenopausal women and men have similar survival rates.
Menstrual irregularities in women and orchitis or epididymitis in men in up to 20% of patients (191) suggest that COVID-19 may influence the reproductive system. Additionally, 6.9% and 1.4% of semen samples were positive for SARS-CoV-2 during the infection and recovery periods, respectively (192,193).
Research revealing low testosterone, oligozoospermia, and immobile sperm in SARS-CoV-2-infected males prompted concerns regarding the effect of COVID-19 on male fertility (194).
Immediate and delayed consequences include testicular discomfort, epididymo-orchitis, or isolated orchitis have all been reported by individuals with COVID-19 (195), consistent with histological results. Similarly, 10.9% of patients in a study (196) with acute COVID-19 reported testicular discomfort. At 1 week to 1-month post-hospitalization, ultrasonography showed orchitis or epididymo-orchitis in more than 20% of 142 males with acute COVID-19 infection, with the risk of epididymo-orchitis rising with COVID-19 severity and advancing age (197). At a median of 80 days after infection, sperm concentration and total sperm count were lower in 55 male patients who had recovered from COVID-19 compared with healthy controls of the same age (198).
There was a correlation between pregnancy and an increased chance of severe COVID-19, which ranged from a 2.5- to 5-fold increase, and an increased risk of mortality, which was 1.7-fold higher. There is not enough evidence to draw a conclusion on whether or whether a pregnancy is also linked to COVID-19 susceptibility (199). The usual risk variables linked with the severity of COVID-19 were significant in pregnant women. These risk factors included a higher body mass index (BMI) and pregestational comorbidities such as diabetes and older maternal age. Furthermore, COVID-19 has the potential to influence maternal and perinatal outcomes. The relative risks of pre-eclampsia/eclampsia, premature delivery, and fetal distress were found to be 1.76 (95% confidence interval [CI]: 1.27–2.43), 1.59 (95% confidence interval [CI]: 1.30–1.94), and 1.70 (95% confidence interval [CI]: 1.06–2.75), respectively (200). On the other hand, research showed an elevated risk for stillbirth but not for premature birth (201). Immunoglobulin M positive in cord blood was found, despite the fact that it is thought that vertical transmission of SARS-CoV-2 infection from mothers to neonates is highly rare (202).
    • Pancreas:
During the SARS epidemic, hyperglycemia in individuals who were not previously known to be diabetic was recorded. During their inpatient hospitalization, 51.3% of nondiabetic patients who were diagnosed with SARS met diagnostic criteria for diabetes (203). Similarly, reports appeared of patients presenting with ketosis, new-onset hyperglycemia, and new diagnoses of diabetes (204). Patients with type 1 or type 2 diabetes were shown to have an elevated risk of death following COVID-19. It has been demonstrated that SARS-CoV-2 is able to infect and proliferate in human endocrine pancreas cells (205), and SARS-CoV-2 viral RNA has been found in the cells of COVID-19 patients at autopsy. In the microvasculature of the pancreas, both the ACE2 receptor and the TMPRSS2 protein have been identified as being present (206).
There have been reports of people developing type 1 diabetes for the first time after COVID-19 (207), with some people maintaining a negative islet cell autoantibody status (208). Therefore, the presence of autoantibody-negative diabetes that requires insulin after COVID-19, in conjunction with the histological results, implies that, at least in some people, COVID-19 may be linked with islet-cell functional impairment or destruction. This is the case even if autoantibodies were not detected in the patients.
Ketoacidosis can develop when there is inadequate insulin release from the pancreas to fulfill the body's glycemic demands. This condition is most seen in people who have type 1 diabetes, which is caused by the death of beta cells by the immune system. Ketoacidosis, on the other hand, has been recorded in individuals with type 2 diabetes mellitus (T2DM) who were treated with COVID-19. However, it is also conceivable that this is a consequence of the high insulin resistance reported in patients with COVID-19 leading to beta cell failure (209). In the majority of instances, ketonemia appeared to be related to insulinopenia (210); however, it is also possible that this is a consequence of the significant insulin resistance observed in patients with COVID-19.
SARS-CoV-2 has been linked to hyperglycemia and ketoacidosis, both of which are more common in individuals who are older and have type 2 diabetes. It can also affect those who have not previously been treated with insulin. While this may be caused by the stress reaction that happens during severe sickness (which is characterized by elevated cortisol and glucagon, which results in a relative insulin deficit), it is also likely that the structure and function of the beta cells are directly damaged. Therefore, it will be important for future studies to further characterize the effects of COVID-19 on dysglycemia, since this will have therapeutic implications.
    • Obesity:
It should not come as a surprise that obesity has emerged as a major problem during the COVID-19 pandemic, given the global prevalence of obesity 13% of the adult population and the well-documented detrimental impacts that obesity has during serious diseases (211). Obesity is linked to increased COVID-19 severity and potentially even death, according to a substantial amount of clinical research that has been conducted, a finding that is corroborated by Mendelian randomization studies (212). It has been reported that patients who were infected with SARS-CoV-2 had a higher overall prevalence of obesity than the general population. This suggests that obesity may make people more susceptible to infection with SARS-CoV-2. It has also been suggested that higher visceral adipose tissue can be used as a predictor of the severity of COVID-19, in addition to BMI (213).
In addition to the influence obesity has on the prognosis of COVID-19, "stay home" tactics used during the pandemic resulted in physical inactivity, stress, sleep deprivation, and bad eating behavior, all of which might lead to an increase in obesity in persons regardless of whether they were infected with SARS-CoV-2. It is possible that older people are at a greater risk of developing "sarcopenic obesity" than younger people because of the hormonal and immunological changes that are associated with aging (214).
There is a correlation between COVID-19 severity and likely mortality in people of all ages who are obese, both men and women. There is a need for more research to identify whether obesity affects the risk of infection and severe COVID-19 and how this occurs.
    • Recent Trends of Severity Compared to The Beginning
WHO nomenclature named coronavirus variants using the letters of Greek alphabets, starting with the Alpha variant, which emerged in 2020. There have been several notable variants since the start of the pandemic, including Alpha, Beta, Delta, and Omicron.
Alpha: The CDC identified Alpha (B.1.1.7) as a variation of concern after its initial appearance in Great Britain in November 2020. According to estimates, the B.1.1.7 lineage was 30 to 50% more contagious than the original SARS-CoV-2 strain.
Beta: By the end of 2020, Beta (B.1.351) was first identified in South Africa and quickly spread to other nations. The U.S. did not see Beta frequently. Beta was reportedly roughly 50% more contagious than the initial coronavirus strain, according to the CDC.
Delta: In late 2020, Delta (B.1.617.2) was discovered for the first time in India; compared to earlier varieties, it was twice as infectious as compared to the prior variants. Hospitalization from Delta was more likely to occur in the unvaccinated. The most well-known of the Delta offshoots was Delta AY.4.2, which is frequently inaccurately referred to as Delta Plus.
Omicron: In the last 2 years, Omicron and its sub-variants have been the most common SARS CoV-2 strains in the United States (22). Several recent Omicron strains in circulation, such as BF.7, XBB, BN.1, and BF.11, are still being studied by experts. Omicron subvariants are thought to be very effective disease carriers, and although researchers are still learning about XBB.1.5, they believe it to be the most transmissible strain to date. One explanation was that the spike protein, which binds to human cells, had more than 30 alterations, many of which are thought to increase the likelihood of infection. The Omicron variant, which has been confirmed to be more transmissible and less virulent than previously circulating variants, has taken over as the dominant strain since 2021 (215,216).
Cases quickly spread to neighboring countries after the initial Omicron strain (BA.1) was found in South Africa and Botswana in late November 2021. By December 2021, Omicron had increased the number of daily cases in the U.S. to over a million. In 2022, several sub-variants, including BA.5, BQ.1, and BQ.1.1, were identified from it. By January 2023, a new Omicron subvariant known as XBB.1.5 was responsible for most infections in the US.
COVID-19 is a complicated illness with symptoms ranging from asymptomatic infection to multiorgan failure. The severity of COVID-19 may alter over time for various causes among the demographics. The introduction of new variants, development, and usage of more effective treatments may have an impact on clinical care and the severity of the disease. The severity of three high-COVID-19 transmission periods has been studied using a variety of surveillance system indicators, including the number of cases, emergency department (ED) visits, admissions, ICU utilization, and deaths.
Total number of cases in the US until May 2023 is 103.37 million. The CDC reviews information from three different surveillance systems and a major healthcare database to evaluate several indicators during three high-COVID-19 transmission periods: December 1, 2020–February 28, 2021 (winter 2020–2021); July 15–October 31, 2021 (predominance of SARS-CoV-2 B.1.617.2 [Delta]), and December 19, 2021–January 15, 2022. (Omicron predominance).
Higher vaccination coverage, which decreases disease severity (217), lower virulence of the Omicron variant (216,218,219), and infection-acquired immunity are all likely major contributors factors to the less severe COVID-19 disease during the Omicron period than previous periods of high transmission (216,220).
The highest weekly case rate per 100,000 population was 516 (December 2020-February 2021), 354 (July-October 2021), and 1696 (December 2021-January 2022). During the Omicron surge, the total cases and the highest percentage of ER visits was 13.6%, the ratio of total cases to the highest hospital admission was 140K and the highest weekly death rate per 100,000 population was 5.23% compared to the winter of 2020-2021 period (7.4%, 125K and 7.4 respectively) and Delta (7.2%, 95K, 4.3 respectively) (67).
A maximum of 20.6% of staffed inpatient beds were used for COVID-19 patients during the Omicron period, which is 3.4% and 7.2% higher than the winter of 2020-21 and during the Delta surge, respectively. The usage of beds in the ICUs did not rise to the same extent, though. During the Omicron surge, 30.4% of staffed ICU beds were in use for COVID-19 patients, which is 1.2% higher than during the Delta surge and 0.5% less than during the winter of 2020-21 (67).
Since December 2021, the Omicron variant has caused a notable rise in COVID-19 cases in the US. Although the sudden increase in cases has put a strain on the healthcare system and led to the most COVID-19-related ED visits and hospital admissions since the outbreak, the disease severity seems to be lower than during prior surges. In addition to decreased rates of ED visits, hospital stays, and fatalities relative to cases seen during the Omicron period, hospitalized COVID-19 patients also had lower levels of severity of illness markers, such as ICU admissions, need for mechanical ventilation, length of stay, and in-hospital mortality. The use of vaccine boosters by recommended subgroups and increases in vaccination coverage among eligible individuals (67,217) are two main contributing factors to the apparent decline in disease severity (67). Another important determinant for less severe disease is infection-acquired immunity (216,220), as well as the potential for decreased virulence of the Omicron variant (216,218,219).
WHO has now classified XBB.1.5 as a VOI. It is a subvariant of Omicron, reported to be identified in 38 countries (221). Although this variant is not associated with severe illness, the present vaccines do not induce high neutralization titers against this variant (222).
    • Evaluation
Detailed history including duration of symptoms, travel, exposure, pre-existing conditions, and substance abuse should be taken by the clinician. In the acute phase of the infection, prompt diagnosis using nucleic acid amplification testing and serologic testing must be done.
  • Nucleic acid amplification testing (NAAT)
Reverse transcription polymerase chain reaction (RT-PCR) is considered the gold standard in the detection of SARS-CoV-2 infection. With a specificity of nearly 100%, the sensitivity can depend on multiple factors including sample source, sample adequacy, and time from exposure (74). NAATs done in the laboratory have a higher sensitivity than point-of-care-based tests. NAATs, that are commercially available, are designed to target multiple virus genomes as opposed to NAATs designed to focus on one target, leading to false negative results when there is a mutation in the genome targeted by the test. SARS-CoV-2 RNA can be detected by NAATs weeks to months after the symptom onset for COVID-19, however, isolation of competent virus beyond 10 days of symptom-onset in mild disease and over 20 days in severe disease is low (223). Hence the Centers for Disease Control and Prevention (CDC) does not support repeat NAATs within 90 days in asymptomatic patients with previous SARS-CoV-2 infection (224).
  • Antigen testing
Antigen-based tests detecting viral antigens have less sensitivity than NAATs but have high specificity. They have a rapid turnaround with a lower cost making it attractive point-of-care testing, especially in crowded living situations like nursing facilities, dormitories, and correctional facilities. False positive results have been identified when the test is completed without following the instructions, human antibodies like rheumatoid factor interfering with the testing, and used in settings with a low prevalence of COVID-19 infection.
  • Antibody or serologic testing
Antibody-based testing detects SARS-CoV-2 antibodies are available for use however not recommended for diagnosing SARS-CoV-2 infection since seroconversion (development of immunoglobulin (Ig) G and IgM to SARS-CoV-2) can take over 21 days. Serologic testing has been utilized when both NAATs and antigen tests have yielded false-negative results.
    • Therapeutics
Need for effective treatments and vaccines
The COVID-19 pandemic brought unprecedented challenges to the scientific and healthcare community. It ushered in the need for effective treatments and vaccines that had to be tested in a real-world setting at a rapid pace. The number of clinical trials has increased exponentially since the start of the pandemic and the number of studies related to COVID-19 is now around 8,700. The trials that are actively recruiting currently are also numerous, approximating around 2,000 in the world (225). Tested therapies are being approved at a rapid rate by regulatory bodies across countries in efforts to stop the spread of the virus and to decrease mortality. Several emergency authorizations have been granted to bring treatments, and global efforts are underway to repurpose drugs to bring treatments to people in an accelerated timeline while awaiting benefits from trials. However, not all trials have been successful. Many of the treatments that may have shown efficacy in earlier trials failed to do so in large randomized controlled trials (RCTs), eg. baloxavir, marboxil, lopinavir/ritonavir, chloroquine, hydroxychloroquine, interferon β-1a, colchicine, favipiravir, ivermectin, ruxolitinib, tofacitinib, metformin, and convalescent plasma. There is also a growing sense of discomfort and criticism about safety, weak methodology, and the power of these trials causing disagreements and debates among clinicians. This review will shed light on the large trials that have shown the success of a certain therapy or a lack of efficacy of others up until this cross-section of time. The readers are urged to continuously update their knowledge and keep up with best practice guidelines in this dynamic and rapidly evolving science.
  • Importance of data sharing
Many institutions, pharmaceutical companies, government agencies, and journals have acknowledged the importance of data sharing in clinical trials. The release of de-identified individual participant data has been particularly emphasized. The European Medicines Agency (EMA) and Health Canada have implemented landmark transparency policies, both of which now post sections of the licensure dossier received by the industry on their websites (226). Additionally, industry and academic platforms, such as ClinicalStudyDataRequest.com (227), Yale University Open Data Access (YODA) Project (228), and Vivli (229), have been created to facilitate third-party access to trial data and documents. Since 2015, the US Institute of Medicine has endorsed the benefits of sharing clinical trial data, emphasizing that verification and replication of investigators’ claims were essential to the scientific process (230).
  • COVID-19 trial challenges
During the initial phase of the pandemic, enrollment and randomization were difficult due to lockdown and social distancing but these later improved. Other external factors such as limitations to resources in certain countries and the changing political landscapes are some of the many hurdles that investigators have faced. There have been recommendations to establish committees, incorporate governance to balance power, centralize funding, and engage community stakeholders by certain groups (231,232).
Currently, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) are the major variants that are present in the community. There are others classified by the WHO as VOI, VOHC, and variants under monitoring (233). The emergence of these variants has changed the standard of care and utilization of new therapies which have affected the outcome of trials and may continue to do so in the future.
  • COVID-19 trials overview
Types of trials (Figure 7):
  • Prevention trials: To evaluate vaccines or other interventions designed to prevent people from getting infected with SARS-CoV-2. These trials typically involve healthy individuals.
  • Treatment trials: Testing treatments for people who have already been diagnosed with COVID-19. Treatments may include drugs, monoclonal antibodies, or other therapies.
  • Diagnostic trials: Testing new diagnostic tests or procedures for COVID-19. These tests can help diagnose early infection and identify individuals who may be asymptomatic carriers of the virus.
  • Prognostic trials: To identify predictors of disease severity, or outcome. They can help identify patients at high risk for severe disease or complications.
  • Observational studies: These studies gather data on patients with COVID-19 and help researchers understand how the disease progresses, how different patient populations are affected, long-term complications from the disease, and which treatments are most effective.
COVID-19 made researchers launch trials sooner than before. For example, the REM-CAP trial used its existing infrastructure and expanded it to include COVID-19 patients. The RECOVERY trial used nationwide electronic health record (EHR) data to assess outcomes (234). Owing to the urgency of the pandemic, several countries implemented fast-track procedures to reduce review processes for trials to be conducted (235). The rapid enrollment in trials such as RECOVERY, ACTT, SOLIDARITY, REM-CAP, HEAL-COVID, PROTECT-CH, PRINCIPLE, COMET-ICE, BLAZE-1 set practice standards for other trials to be conducted in an expedited manner and for phase-2 trials to supply data to phase 3 trials in a prompt fashion. Large pragmatic innovative trials like RECOVERY made it possible for multiple treatment arms to be conducted simultaneously. The framework of these ‘Trials Within Cohorts (TWiCs)’ could potentially be used for future research and other endemics. Table 2 below shows the large trials conducted in the past few years.
  • Importance of ongoing trials to fight COVID-19
There is a need for further research in various fields for the effective management of high-risk patients and complications. The emergence of new variants of the virus is hindering the usefulness of existing drugs. COVID-19 in immunosuppressed states, malignancies, inherited or acquired immunodeficiencies, and solid organ transplants have a particularly devastating course and need further therapies to improve outcomes. It is possible that in the future, certain COVID-19 study platforms will remain and evolve to address other infections. Long COVID is presently a major cause of disability. This complex post-COVID entity is more severe than other post-viral syndromes. There are some antifibrotic drugs or anti-inflammatory drugs that are currently being studied to prevent Long COVID (263). While countless studies have improved our understanding of COVID-19, there remain so many unanswered, unknown variables and we are optimistic that they will be answered in future trials.
  • Medications
In this review, we discuss the various treatment options for COVID-19 infection with emphasis on the management of patients with an immunocompromised state (transplant, cancer), HIV, pregnancy, and co-infection with influenza.
Since the beginning of the pandemic, multiple medications have been utilized in the treatment of patients diagnosed with COVID-19 infection as listed in Table 3.
  • Antivirals
The U.S. Food and Drug Administration (FDA) has approved the use of Remdesevir and issued an Emergency Use Authorization (EUA) for Paxlovid and Molnupiravir in patients who test positive for COVID-19 with mild to moderate symptoms (not requiring supplemental oxygen or an increase in home oxygen, non-hospitalized patients).
Remdesevir is a nucleotide analogue with an inhibitory function against SARS-CoV-2 (264). During the early phase of the pandemic, a study (Beigel et al. 2020) showed that remdesevir shortened the time to recovery in patients admitted with severe COVID-19 receiving supplemental oxygen therapy (265), which was later shown to be ineffective in patients symptomatic for over 7 days and requiring supplemental oxygen(245). WHO recommended against the use of remdesevir in hospitalized patients citing no benefits in clinical outcomes (239). A recent trial (266) showed that 3-day outpatient treatment with intravenous remdesevir resulted in an 87% reduction in the risk of hospitalizations or death in patients with symptoms for < 7 days.
Ritonavir-Boosted Nirmatrelvir (Paxlovid) - Nirmaltrelvir is an oral SARS-CoV-2 Mpro inhibitor (267), packaged with ritonavir (cytochrome P450 (CYP) 3A4 inhibitor and a boosting aged used for HIV protease inhibitors) to increase the concentration of nirmatrelvir to the desired therapeutic range (268). Paxlovid can be used in high-risk symptomatic COVID-19, non-hospitalized patients resulting in a lower risk of progression to severe COVID-19 (251). Caution must be used to assess the safety of Paxlovid (ritonavir component) due to concern for significant drug-drug interactions. As of May 25, 2023, Paxlovid is the first oral antiviral drug approved by the FDA for use in patients at high risk for progression to severe COVID-19, including hospitalization or death.
Molnupiravir is an oral ribonucleoside, a prodrug of beta-D-N4-hydroxycytidine (NHC) with antiviral activity against SARS-CoV-2. Molnupiravir is approved for use in non-hospitalized patients at high risk for disease progression, starting within 5 days of the onset of symptoms (269). A meta-analysis (270) showed that patients receiving molnupiravir had reduced all-cause mortality, and risk of hospitalizations, and improved proportions of patients testing negative by day 5 for viral RNA. It is recommended to be used only in situations when both remdesevir and paxlovid are not available.
Interferons are cytokines with antiviral properties. Studies conducted during the early phases of the pandemic (271–273) administered interferons in addition to other drugs for COVID-19 such as hydroxychloroquine, lopinavir/ritonavir, and ribavarin. Randomized controlled trials did not show the clinical benefit of adding interferon to remdesevir, with likely worse outcomes in patients needing high-flow oxygen therapy (274) along with no reduction in length of stay, need for mechanical ventilation, or mortality (275).
  • Antibody Products
Monoclonal antibodies (mAbs) which target the SARS-CoV-2 spike protein, have shown some clinical benefits in treating COVID-19 infection. Four neutralizing mAbs received EUA previously include bamlanivimab with etesevimab, bebtelovimab, casirivimab with imdevimab, and sotrovimab. Since the emergence and dominance of Omicron and the unknown efficacy of these drugs against this variant, they are currently not approved for use.
Bamlanivimab with etesevimab is neutralizing antibodies obtained from the convalescent plasma of patients who recovered from COVID-19 infection in North America and China, respectively. Etesevimab binds to a different epitope compared to bamlanivimab and is shown to neutralize variants with resistant mutations on the epitope bound to bamlanivimab (276). Results from the phase 3 portion of BLAZE-1 suggested an 87% reduction in COVID-19-related hospitalizations or death in patients in the treatment group as compared to the patients receiving placebo (277).
Bebtelovimab is a potent anti-spike neutralizing antibody with activity against all known SARS-CoV-2 variants of concern in vitro (278). In the ongoing phase 2 portion of the BLAZE-4 trial, non-hospitalized patients with mild to moderate COVID-19 treated with bebtelovimab alone or combined with bamlanivimab and etesevimab showed significant reductions in viral load and reduced time to sustained symptom resolution (255).
Casirivimab with imdevimab (REGEN-COV) is an antibody combination that significantly reduced COVID-19-related hospitalizations or all-cause mortality compared to a placebo (256).
Sotrovimab is also a potent anti-spike neutralizing antibody targeting a region of the SARS-CoV-2 epitope not competing with the binding of the angiotensin-converting enzyme 2 (279). In the COMET-ICE study, non-hospitalized patients with mild to moderate COVID-19 were randomized to either receive sotrovimab or placebo. All-cause hospitalization and death were significantly reduced in the patients receiving sotrovimab (279).
Tixagevimab and Cilgavimab (Evusheld) are long-acting monoclonal antibodies used as pre-exposure prophylaxis for COVID-19 in patients ineligible for vaccinations due to severe allergy or immunocompromized states. Preliminary data from the PROVENT trial suggests a significant reduction in the risk of experiencing symptomatic COVID-19 infection when patients were treated with tixagevimab and cilgavimab compared to placebo (280).
COVID-19 Convalescent Plasma (CCP) obtained from the plasma of patients recovered from COVID-19 infection has received the US FDA EUA for immunocompromised patients in hospitalized or non-hospitalized settings. Several randomized controlled trials (281–283) evaluating the use of high-titer CCP in immunocompetent patients hospitalized with COVID-19 showed no benefit, resulting in the early discontinuation of these studies. Although there is limited evidence to support its use in the immunocompromised (283,284), a recent systematic review and meta-analysis (Senefeld et al. 2023), suggested a mortality benefit in immunocompromised patients with COVID-19 (285).
  • Immunomodulators
Corticosteroids remain the standard of care for patients with severe COVID-19 infection requiring hospitalization and oxygen therapy. They help diminish the systemic inflammatory response seen in COVID-19 infection leading to lung injury along with multi-organ failure. They have been shown to improve clinical outcomes along with a reduction in mortality in patients hospitalized with COVID-19, requiring supplemental oxygen therapy (286,287). In the RECOVERY trial, hospitalized patients with COVID-19 receiving respiratory support ranging from supplemental oxygen to mechanical ventilation and receiving oral or intravenous dexamethasone for up to 10 days had lower mortality compared to the patients receiving usual care without any respiratory support (240). In a study (Crothers et al. 2022), the early use (within 48 hours) of dexamethasone in hospitalized patients with COVID-19 on no respiratory support or only nasal cannula oxygen did not provide mortality benefit with concern for potential harm (288). Inhaled budesonide and ciclesonide used in the outpatient setting in COVID-19 patients did not consistently alleviate symptoms of COVID-19 infection and had no effect on the rate of hospitalization or death (289–292).
Interleukin-6 (IL-6) Inhibitors include anti-IL-6 receptor monoclonal antibodies (sarilumab, tocilizumab) and anti-IL-6 monoclonal antibodies (siltuximab). IL-6 are proinflammatory cytokines produced by the fibroblasts, lymphocytes and monocytes. COVID-19 infection is associated with a surge in cytokine release such as C-reactive protein (CRP), D-dimer, ferritin, and IL-6, which is responsible for the widespread inflammation, particularly respiratory failure (293,294).
Tocilizumab is a recombinant anti-IL-6 receptor monoclonal antibody approved for use in patients with rheumatologic disorders, chimerin antigen receptor T cell therapy-induced cytokine release syndrome (CRS) and select hospitalized patients with COVID-19 infection. In both RECOVERY and REMAP-CAP trials, survival benefit was seen in patients experiencing rapid respiratory failure and elevated CRP levels receiving tocilizumab as compared to the standard of care (295,296). However, in a double-blind randomized controlled trial assessing the use of tocilizumab and remdesevir to placebo and remdesevir, tocilizumab did not shorten time to hospital discharge and was not associated with reduced mortality (242).
Sarilumab is also a recombinant anti-IL-6 receptor monoclonal antibody approved for the management of rheumatoid arthritis. In a phase 3 trial (297), sarilumab failed to show mortality benefit in hospitalized patients with COVID-19 requiring supplemental oxygen therapy. In the REMAP-CAP trial, like tocilizumab, sarilumab showed a higher likelihood of survival during the hospitalization in addition to have greater organ support-free days (296). Sarilumab use is recommended only during the non-availability or inability of tocilizumab use.
Siltuximab is a recombinant IL-6 monoclonal antibody that results in the inhibition of IL-6 signaling by preventing the binding of IL-6 to both membrane-bound and soluble IL-6 receptors. They are approved for use in Castleman disease. Due to the limited availability of data on the efficacy of siltuximab, they are not recommended for use in patients with COVID-19 infection.
Janus Kinase (JAK) Inhibitors interfere with the phosphorylation of signal transducer and activator of transcription (STAT) proteins, hence stunting cellular signaling, growth, and survival (298). They are involved in preventing immune activation, and inflammation by the release of proinflammatory cytokines, and by inhibiting the phosphorylation of the signal transduction proteins, thus showing a role to play in the treatment of COVID-19 (299). Multiple JAK inhibitors including baricitinib, tofacitinib, and ruxolitinib have been studied for the treatment of COVID-19 however only baricitinib and tofacitinib are recommended for use.
Baricitinib is a selective JAK1 and JAK2 inhibitor. It is thought to impart its antiviral effects by preventing the entry of SARS-CoV-2 into the lung alveolar epithelial cells (300). Baricitinib is FDA-approved for use in rheumatoid arthritis and hospitalized COVID-19 patients requiring oxygen therapy including patients on non-invasive ventilation (NIV), mechanical ventilation, or ECMO. In both RECOVERY and COV-BARRIER trials (301,302), the use of baricitinib showed survival benefits in hospitalized patients receiving supplemental oxygen via a high-flow device or non-invasive ventilation, with additional benefits noted in patients on mechanical ventilation in the latter trial. In the ACTT-2 and ACTT-4, baricitinib was shown to be potentially beneficial however neither trial evaluated the benefit with the use of dexamethasone (303,304).
Tofacitinib is a selective inhibitor of JAK1 and JAK3, with some activity against JAK2. It is FDA-approved for rheumatoid arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, and ulcerative colitis. In a double-blind, placebo-controlled randomized trial (305), treatment with tofacitinib, as compared to placebo, carried a lower risk of mortality or respiratory failure in the hospitalized patients with COVID-19, a majority of whom were treated with systemic glucocorticoids.
Bruton’s Tyrosine Kinase (BTK) Inhibitors are B-cell and cytokine receptor signaling molecules approved by the FDA to treat various B-cell malignancies. The three drugs in this class include acalabrutinib, ibrutinib, and zanubrutinib.
Heparin: COVID-19 has been associated with an increased incidence of thrombo-embolic events resulting in increased mortality (294). Therefore, all individuals who are hospitalized with COVID-19 should receive thrombus prophylaxis with low-molecular-weight heparin or unfractionated heparin. Recommendations regarding doses have changed during the pandemic depending on disease severity. It is important to consider individual risk assessment while deciding the anticoagulation in these patients (306). Based on the analysis of recent trials (ACTION, RAPID, HEP-COVID), in hospitalized non-ICU patients, therapeutic dose of anticoagulation has been associated with better outcomes (307–309). So current guidelines suggest the use of a therapeutic dose of anticoagulation for prophylaxis if not contraindicated otherwise. Dose adjustment may be needed based on individual risk factors. In ICU patients, a prophylactic dose of anticoagulation is preferred (243). COVID-19 patients who are already on therapeutic anticoagulation should not reduce the dose unless there is contraindication. Anticoagulation continuation is not recommended on discharge in either group.
Aspirin or other antiplatelets (Plavix/Ticagrelor) are not recommended for the treatment of patients with COVID-19 in either inpatient or outpatient based on major trials including RECOVERY, ACTIV-4A, and ACTIV-4B. Individuals who are already on antiplatelet therapy for other indications may continue it, if not contraindicated otherwise (310).
Colchicine: Oral colchicine did not show a significant reduction in mortality based on RCTs including over 4000 patients. The use of colchicine in the treatment of COVID-19 is not recommended (311).
Fluvoxamine is an antidepressant medication and its use for the treatment of COVID-19 has not been recommended. RCT in patients with mild to moderate COVID-19 did not show significant benefit with fluvoxamine (312).
Vitamin C is not associated with a reduction in the incidence or severity of COVID-19.
Vitamin D has no benefit in the treatment of COVID-19.
Zinc may decrease the duration of symptoms in mild COVID-19 but does not have enough evidence regarding improving outcomes (313). Intranasal use of zinc may result in hyposmia or anosmia.
  • Management of Respiratory Failure in COVID-19
All patients with COVID-19 should be monitored closely for any signs of respiratory decompensation using pulse oximetry (SpO2) as progressive respiratory decline can lead to acute respiratory distress syndrome (ARDS) and eventually multi-organ failure and death.
  • Monitoring Oxygenation
The target SpO2 to be maintained in patients with COVID-19 remains largely unclear. In patients with hypoxemia, the goal of providing supplemental oxygen therapy should be to maintain SpO2 between 92-96% (314). A systematic review and meta-analysis of 25 randomized controlled trials (315) showed that liberal oxygen supplementation in patients with respiratory failure without COVID-19 to maintain SpO2 around 94-96% was associated with increased mortality. In a recent study (Barrot et al. 2020), conservative oxygen therapy to maintain SpO2 between 88 to 92% in patients with ARDS without COVID-19 did not show increased survival at 28 days (316). However, caution must be exercised while interpreting SpO2 in patients with dark skin as occult hypoxemia may go undetected in these patients by pulse oximetry (317).
  • Acute Hypoxemic Respiratory Failure
COVID-19 is frequently associated with acute respiratory failure with varying degrees of hypoxemia. Conventional oxygen supplementation can be inadequate to meet the oxygen demands in these patients, prompting escalation of respiratory support with a variety of modalities including high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), intubation and mechanical ventilation (MV), or extracorporeal membrane oxygenation (ECMO).
  • High-flow nasal cannula (HFNC) oxygen therapy
HFNC therapy involves delivery, to the nose, of a blend of humidified and heated oxygen and air at high flow rates (318). In a study (Frat et al. 2015) 310 patients with acute hypoxemic respiratory failure were randomly assigned to HFNC, oxygen therapy via a face mask, or NIV. Primary outcome of rate of intubation at day 28 did not differ amongst any of the three modalities of treatment, however patients receiving HFNC therapy experienced a significantly lower risk of death at 90 days (319). Subsequently, a systematic review and meta-analysis of 8 trials totaling 1084 patients showed that the rate of intubation and ICU mortality was lower in patients treated with HFNC in comparison to conventional oxygen therapy and NIV (320).
Since the beginning of the pandemic, multiple studies have reported on the utility of HFNC in the management of respiratory failure with COVID-19. A randomized clinical trial evaluating 220 patients with severe COVID-19 found that the rate of intubation and time to clinical improvement was significantly lower in patients treated with HFNC oxygen therapy compared to conventional oxygen therapy (321).
  • Non-invasive Ventilation
Bilevel Positive Airway Pressure (BiPAP) and Continuous Positive Airway Pressure (CPAP) constitute the non-invasive ventilation utilized in the management of respiratory failure from COVID-19. Determination of the ideal timing of initiation of this modality, in comparison with HFNC, in COVID-19 patients with progressive respiratory failure remains unclear to date. Furthermore, NIV is an aerosol-generating procedure and may be associated with an increased risk of nosocomial transmission of SARS-CoV-2 (322).
In the HENIVOT study involving 109 patients with COVID-19-associated moderate to severe respiratory failure, NIV via a helmet device, as compared to HFNC, did not lead to a significant difference in respiratory support-free days however was associated with lower rates of endotracheal intubation which was statistically significant (323).
RECOVERY-RS was a large trial evaluating 1273 patients randomized to use either CPAP or HFNC for acute respiratory failure with hypoxemia due to COVID-19 in comparison to conventional oxygen therapy. The primary outcomes of endotracheal intubation or 30-day mortality were significantly lower only in patients receiving CPAP as compared to conventional oxygen therapy, thus favoring CPAP as the initial strategy of management of respiratory failure in COVID-19 (324). The results of this study need careful interpretation as it was terminated early and hence underpowered, coupled with the crossover between the groups.
  • Prone Positioning
In patients with moderate to severe ARDS needing mechanical ventilation, early prone positioning (PP) has been associated with improved oxygenation and outcomes as seen in the PROSEVA randomized controlled trial (325). PP has resulted in improved oxygenation in COVID-19 patients needing supplemental oxygen or NIV, with some reports of a lower need for intubation (326,327).
Awake Prone Positioning Meta-Trial Group (Ehrmann et al. 2021) is the largest trial to date including 1126 patients who were randomized to either PP along with HFNC or standard care (HFNC alone). Patients had a lower incidence of intubation by day 28 in the PP group vs the standard care group, however, no difference was seen in the 28-day mortality between the groups. The median duration of awake PP was about 5 hours and longer durations of awake PP resulted in treatment success by day 28 (328).
A systematic review and meta-analysis (Munshi et al. 2017) of 8 randomized controlled trials totaling 2129 patients with ARDS evaluating the use of PP (329). Patients in the PP group for >12 hours had lower mortality compared to the supine position group and PP was noted to improve oxygenation in all the trials.
  • Mechanical Ventilation
In COVID-19 patients with progressively worsening acute hypoxemic respiratory failure, mechanical ventilation should be offered when all other non-invasive modalities of improving oxygen fail. Akin to ventilator management in ARDS, positive end-expiratory pressure (PEEP) plays a significant role in COVID-19 patients by improving oxygenation, preventing alveolar collapse, and reducing atelectrauma, thus minimizing ventilator-induced lung injury.
In the pre-pandemic systematic review and meta-analysis of 3 trials (Briel et al. 2010), the management of ARDS with high vs low PEEP was compared. The results suggested that higher levels of PEEP were associated with lower rates of ICU mortality and in-hospital mortality (330).
In COVID-19 patients with ARDS (CARDS), despite the moderate to severe ARDS, lung compliance can vary dramatically from normal to low compliance, as typically seen in non-COVID-19 etiologies. In a case series by (Tsolaki et al. 2020) applying higher PEEP (>10 cm H2O) in CARDS with normal lung compliance was detrimental as it resulted in a significant increase in pleural pressure leading to a decline in venous return leading to hemodynamic compromise. Thus, individualized ventilator management based on the patient’s respiratory and hemodynamic status must be formulated to ensure the best patient outcomes (331).
  • Extracorporeal Membrane Oxygenation (ECMO)
ECMO is a type of cardiopulmonary life support, which involves drawing blood from the vascular system, pumping it through the exterior of the body, and then reinfusing it back into circulation. Hemoglobin fully saturates with oxygen outside the body, and CO2 is expelled. The rate of countercurrent gas flow through the oxygenator determines oxygenation, and the amount of CO2 eliminated may be regulated by changing that rate (332). Indications for ECMO use can be cardiac failure, respiratory failure, or a combination of both (333).
In patients with CARDS and worsening hypoxemia refractory to other modalities, ECMO has been utilized with inconclusive results regarding respiratory outcomes and mortality. (329,334,335) In a pre-pandemic (Combes et al. 2018) ECMO use in ARDS did not result in lower 60-day mortality (335).
In a retrospective analysis of 4812 patients treated with ECMO for CARDS, a higher 90-day mortality was noted (244). Given the lack of controlled trials evaluating ECMO use in patients with CARDS, their benefits remain unproven at this time.
  • Vaccinations
Immunizations (or vaccinations) are one of the most effective preventive health measures. It is a safe, simple, and effective way to protect populations against harmful diseases.
There are two categories of COVID-19 Vaccines: Component Viral Vaccines and Whole Virus Vaccines (Figure 8).
Component viral vaccines consist of isolated and purified viral protein subunits, virus-like particles (VLP) that mimic the structure of the virus without the genetic materials, are DNA-based and RNA-based, and replicating and non-replicating viral vectors.
Whole virus vaccines are inactivated (contain killed viral copies), and live-attenuated (contain weakened viral copies).
The WHO has granted Emergency Use Listing (EUL) for 11 vaccines as listed in Table 4. For the purpose of this review, all the vaccines under EUL will be discussed in detail. Additionally, about 50 vaccines that have been approved worldwide in at least one country are listed in Table 5.
(i) COVOVAX: Developed by the Serum Institute of India, received WHO EUL on 17 December 2021, approved for use in 12 years and older. This vaccine has the same formulation as the Novavax vaccine (NVX-CoV2373). EUL in 6 countries - Bangladesh, India, Indonesia, Philippines, South Africa, and Thailand. Currently has three phase-2 trials, and four phase-3 trials (https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65971)
The phase 3, observer-blinded, randomized, active-controlled study in adults of more than or equal to 18 years of age in India who have already received primary vaccination against COVID-19 at least 6 months ago (6 months or 180 days from the second dose), to evaluate the immunogenicity and safety of the COVOVAX booster dose in comparison with the control vaccine. A total of 372 eligible participants of ≥ 18 years of age who have completed a primary 2-dose schedule of COVID-19 vaccination at least 6 months ago will be enrolled in this study in 2 cohorts of 186 participants each with 1:1 allocation to COVOVAX or control vaccine. The primary outcome is to evaluate titers of Anti-S IgG and Neutralizing antibodies 28 days after vaccination.
(ii) Nuvaxovid (Novavax): Also referred to as NVX-CoV2373, developed by the Serum Institute of India, received WHO EUL recommendation on 20 December 2021 in 40 countries. There are a total of 22 registered trials in 14 countries consisting of 2 phase 1 trials, 11 phase 2 trials, and 9 phase 3 trials. COVID-19 vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
(iii) Spikevax: Developed by Moderna, is an mRNA vaccine (nucleoside modified), approved in 88 countries. 70 trials in 70 countries, 10 phase 1, 36 phase 2, and 24 phase 3 trials.
(iv) Comirnaty: Developed by Pfizer/BioNTech, is an mRNA vaccine (nucleoside modified) for use in individuals aged 16 years and older. It is the first vaccine that was approved by FDA for emergency use in December 2020. Currently, it is approved in 149 countries with over 100 trials in 31 countries, 17 phase 1 trial, 54 phase 2 trials, and 29 phase 3 trials.
(v) Convidecia: Developed by CanSino Biologics Inc, is a Non replicating viral vector vaccine for use in individuals aged 18 years to 59 years old. It is approved for use in 10 countries with 14 trials in 6 countries, 4 phase 1 trial, 6 phase 2 trials, and 4 phase 3 trials.
(vi) Jcovden/ Janssen: Developed by Johnson & Johnson, is a non-replicating viral vector vaccine for use in individuals aged 18 years and older. It is approved for use in 113 countries with 26 trials in 25 countries, 6 phase-1 trials, 12 phase-2 trials, and 8 phase-3 trials.
(vii) Vaxzevria: Developed by Oxford/AstraZeneca and Verity/SII (COVISHIELD), is a nonreplicating viral vector-based vaccine. It is approved for use by ages 18 and older. Vaxzevria has been shown to have an efficacy of 72% against symptomatic SARS-CoV-2 infection, as shown by the primary analysis of data irrespective of interdose interval from trial participants receiving 2 standard doses with a varying interval from about 4 to 12 weeks. Vaccine efficacy appeared to be higher when the interval between doses was longer. It is the ChAdOx1 virus, made from a weakened version of a common cold virus (adenovirus) causing infections in chimpanzees. It is currently approved in 149 countries. There are 73 ongoing trials in 34 countries.
(viii) Covishield: Developed by the Serum Institute of India, is a nonreplicating viral vector-based vaccine. Consisting of the same formulation as the Oxford/AstraZeneca vaccine (AZD1222), it also contains the ChAdOx1 virus. In addition, genetic material from the Spike glycoprotein has been added to the ChAdOx1 construct. In pooled data from four trials, this vaccine had a protective efficacy of 67% (95% confidence interval [CI]: 57%-74%) for preventing symptomatic and laboratory-proven COVID-19 and nearly 100% (72–100%) for preventing hospitalizations and severe infections, beginning 21 days after the second dose. Covishield has accounted for nearly 88% of all doses in the country to date and has been the sole vaccine used in some areas. Covishield is approved in 49 countries. There are 6 ongoing trials in 1 country.
(ix) Covaxin: Developed by Bharat Biotech, this is an inactivated SARS-CoV-2 antigen (strain NIV-2020–770) approved for use aged 18 and older. There are currently 16 trials in 2 countries. Vaccine efficacy was 78% against COVID-19 of any severity, measured 14 or more days post-dose 2. Vaccine efficacy against severe disease is 93%. The efficacy was 79% in adults aged less than 60 years, and 68% in those aged 60 years and over.
(x) Covilo: Developed by Sinopharm (Beijing), this is an inactivated antigen of the SARS-CoV-2 WIV04 strain. A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%. WHO recommends an interval of 3-4 weeks between the first and second dose of primary series. A booster dose may be considered 4-6 months after the completion of the primary vaccination series, starting with the higher priority use groups, in accordance with the WHO Prioritization Roadmap. There are currently 39 trials in 18 countries.
(xi) CoronaVac: Developed by Sinovac Life Sciences Co., Ltd, this is an inactivated SARS-CoV-2 Virus (CZ02 strain). A phase 3 trial in Brazil reported that two doses, administered 14 days apart, was 51% efficacious against symptomatic SARS-CoV-2 infection, 100% against severe COVID-19, and 100% against hospitalization starting 14 days after receiving the second dose. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends the use of the Sinovac-CoronaVac vaccine in 2 doses (0.5 ml) given intramuscularly, an interval of 2–4 weeks between the two doses of the primary series. SAGE also recommends an additional dose of the Sinovac vaccine be offered to people aged 60 and over as part of an extension of the primary series. Current data does not support the need for an additional dose in persons under 60 years of age. There are 42 trials in 10 countries.
  • COVID-19 in special circumstances
Clinical risk factors including diabetes, hypertension, chronic kidney disease, obesity, cancer diagnosis, and immunosuppression have been associated with COVID-19 disease progression and death in retrospective studies. However, the risk of immunosuppression on COVID-19 disease outcomes, independent of age and comorbidities, is incompletely understood.
  • Immunocompromised state
There were several observational studies comparing the implications of COVID-19 in immunocompromised and the general population. In most of these studies, immunocompromised hosts included, (i) patients undergoing active treatment for solid tumor and hematologic malignancies; (ii) recipients of solid-organ transplants; (iii) active treatment with high-dose corticosteroids, alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory; (iv) moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome); and (v) advanced or untreated HIV infection (HIV and CD4 cell counts less than 200/mm3) (336).
There is no evidence that immunosuppression is associated with increased mortality, especially when the well-known risk factors of age and other comorbidities are adjusted in the statistical models, however, several studies support increased incidence of hospitalizations and prolonged recovery time.
Factors associated with higher odds of hospitalization included older age, comorbidities (hypertension/cardiovascular disease, diabetes, lung disease, renal impairment), and chronic oral glucocorticoid use (prednisone equivalent ≥10 mg/day, OR 2.05, 95% CI 1.06 to 3.96). The use of disease-modifying antirheumatic drugs (DMARDs), that is, no anti-cytokine biological therapies or JAK inhibitors, was associated with a reduced risk of hospitalization (337).
For the treatment of SARS-CoV-2 in people with immunocompromised states, there is no evidence to suggest that these patients should be treated any differently than the general population. Due to the longer shedding durations in immunocompromised persons, a longer course of antivirals, or initiation later in the disease, may be warranted, although these strategies are unstudied. Baseline immunosuppression may be dose-reduced, held, delayed, or replaced with COVID-19-specific therapy such as dexamethasone (338).
In summary, immunosuppressed people are not at increased risk of mortality from COVID-19, when compared with age-matched and comorbidity-matched controls but are at higher risk of hospitalization from COVID-19.
  • Pregnancy
Pregnant women are not any more susceptible to SARS-CoV-2 compared to the general population. Over 90% of the infected pregnant women recover without being hospitalized. However, being pregnant appears to heighten the possibility of a severe clinical course of COVID-19 (increased risks of ICU admission, mechanical ventilation, and death) compared to non-pregnant women of the same age (339). When compared to symptomatic non-pregnant women of reproductive age, pregnant women appear to be at an elevated risk of serious illness and mortality due to the possibility of rapid clinical deterioration (340,341). Older age (≥35 years), underlying medical comorbidities (hypertension, diabetes), obesity, and being unvaccinated are risk factors for serious illness and mortality in pregnancy (342).
In a case-control study of 5183 pregnant and matched 5183 non-pregnant females, after propensity score matching for asthma, chronic obstructive lung disease, cardiovascular disease, chronic renal illness, diabetes, hypertension, obesity, smoking, immunosuppression, age, language, country, health insurance, an increased risk for death (1.5 versus 0.8 percent; OR 1.84, 95% CI 1.26-2.69), pneumonia (9.9 versus 5.6 percent; OR 1.86, 95% CI 1.60-2.16), intubation (8.1 versus 8.6 percent; OR 0.93, 95% CI 0.70-1.25), and ICU admission (13 versus 7.4 percent; OR 1.86, 95% CI 1.41-2.45) were observed (343).
In a retrospective cohort study including data from 463 hospitals in the US, maternal mortality during childbirth hospitalization prior to the pandemic rose from 5.2 deaths per 100,000 pregnant patients to 8.7 deaths per 100,000 pregnant patients during the pandemic (March 1, 2020, to April 31, 2021; OR 1.75, 95% CI 1.19-2.58) (344).
The concern for mother-to-child transmission (vertical transmission) of COVID-19 infection is reported to be less than 2% and the risk factors for such a transmission included severe COVID-19, admission to ICU, postnatal infection, and death (341). There is minimal co-expression of ACE-2 and TMPRSS2 in the placenta, making the entry of SARS-CoV-2, subsequent infection, and fetal transmission very infrequent (345).
The risk of developing preeclampsia is higher in women with COVID-19 infection during pregnancy, even in asymptomatic patients. A meta-analysis of 26 observational studies including over 780,000 pregnant women with SARS-CoV-2 infection showed a 62% higher risk of developing preeclampsia (7 vs 4.8%; odds ratio [OR] 1.62, 95% CI 1.45-1.82) (346).
Preterm and cesarian births were more likely in neonates delivered by mothers with symptomatic COVID-19 (342), with fever and hypoxemia implicated in the increased risk of preterm labor, premature rupture of membranes, and abnormal fetal heart rate patterns (347).
Pregnant patients with COVID-19 were at a higher risk for stillbirth in an analysis of over 1.2 million delivery hospitalizations in the US including over 8000 stillbirths from March 2020 to September 2021 (348). The risk of miscarriage and congenital anomalies is not increased in pregnant patients with COVID-19.
  • Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS)
In the early pandemic phase, reports suggested that HIV patients had no significant differences in clinical outcomes when infected with COVID-19 as compared to the general population (349,350). However subsequent reports suggest that HIV patients with COVID-19 are prone to worse outcomes.
Low CD4 counts or low CD4 nadirs were linked to negative outcomes (ICU admission, mechanical ventilation, and death), and this elevated risk was seen in individuals who had achieved virologic suppression of HIV (351). It must be noted that lymphopenia is often seen in patients with COVID-19 infection, hence obtaining CD4 counts may not reflect a patient’s HIV disease stage accurately.
After controlling for demographics, smoking, and the presence of comorbidities, database research of more than 1 million COVID-19 cases in the United States found that COVID-19-associated hospitalization and death were greater in patients with HIV than in those without HIV (352).
COVID-19 management in patients with HIV does not differ from the general population. Close monitoring of potential drug-drug interactions between antiretroviral treatments (ART) and COVID-19 treatments must be maintained. Dexamethasone use should be done in consultation with HIV specialists and should be restricted to only one dose in HIV patients on rilpivirine as part of the ART as it could lower the levels of rilpivirine.
HIV patients on ART must be encouraged to continue taking them, as treatment interruption may lead to rebound viremia. New HIV patients or those not on ART, with COVID-19) must be started on ART after a discussion with an HIV specialist since the timing of initiation of ART in these patients remains unclear (353).
  • COVID-19 and mental health
It is well known from prior studies that, natural disasters and economic crises result in an increased diagnosis of anxiety, depression, post-traumatic stress disorders (PTSD), substance abuse, and suicidal tendencies (354,355). During the COVID-19 pandemic, the mandatory isolation following the diagnosis, prolonged hospitalization, the ensuing stigma and discrimination, and a lack of social support influence mental health in this population (356). In a study involving over 2000 healthcare workers compared to over 250 non-clinical staff, there were notable differences in terms of the intensity of dread, anxiety, and depression. Additionally, front-line medical staff with frequent contact with infectious patients, such as those working in the emergency department, infectious disease, and ICU, demonstrated higher scores on the fear Hamilton Anxiety Scale (HAMA), and the Hamilton Depression Scale (HAMD), and they were 1.4 times more likely to experience fear and twice as likely to experience anxiety and depression compared to non-clinical staff (357).
Patients with a diagnosis of COVID-19, and those who survive the infection, are at an increased risk of psychiatric symptoms and disorders. In a retrospective study (358) analyzing the administrative health care data, the investigators looked at the risk of incident mental illnesses in patients (n > 150,000) who survived COVID-19 for 30 days and patients (n > 5,600,000) without COVID-19. After adjusting for potential confounding factors (e.g., age, smoking status, and general medical comorbidities), there was an increased risk of a psychiatric diagnosis in patients surviving COVID-19 (hazard ratio [HR] 1.46, 95% CI 1.40-1.52). The most common issues encountered in these patients were cognitive dysfunction, anxiety, depression, post-traumatic stress disorder, sleep disorders, and substance abuse.
Since the epidemic, there has been a rise in microaggressions, hate crimes, verbal attacks, and acts of physical violence committed against Asian Americans (359). This fact must be acknowledged. Exclusionary policies, disparaging rhetoric, and implicit encouragement at federal and institutional levels, which act to perpetuate anti-Asian violence and xenophobia, have resulted in the stigmatization of persons of Asian origin as a result of the global health crisis (360).
  • Long-term Effects, Complications, and Mortality
Nearly 3 years since the start of the pandemic, there has been new information about the long-term complications of COVID-19, especially Long COVID-19. A proportion of patients have been noted to have a similar symptom profile that persists long after they have recovered from the infection without returning to their baseline health. Recovery is confirmed by negative virus isolation tests. According to the CDC, post-acute COVID-19 is the term used to describe these symptoms which last for more than four weeks after the initial infection. It includes long COVID-19, multiorgan effects, and effects of treatment. COVID-19 has effects on various organ systems which have been discussed in detail below. The effects of treatment are like the sequela of any severe infection including deconditioning, PTSD, and weakness.
Long COVID can be further divided based on the time duration as subacute (up to 12 weeks from the infection) and chronic (when symptoms persist more than 12 weeks) (361).
The Long COVID-19 is known to affect all major organ systems not limited to cardiorespiratory but including neurological, renal, musculoskeletal, endocrine, and gastrointestinal systems (Table 6). It is a constellation of symptoms that mainly includes fatigue (seen in more than 50% of patients) and shortness of breath. Other symptoms include arthralgias, cognitive delay, mental health disorders, altered smell and taste, chronic dry cough, sleep disturbances, and hair loss. It is also known to affect survivors irrespective of their disease severity (362). This syndrome of fatigue post-infection is very common with various viruses such as MERS (Middle East Respiratory Syndrome), SARS (Severe Acute Respiratory Syndrome), Influenza, Ebola virus, and EBV to name a few (363). Long COVID affects people of all age groups although some studies noted a correlation between older age, female sex, severity of symptoms, need for oxygen, and comorbidities especially respiratory conditions (364,365). COVID-19 is known to have a milder effect on children. Studies show that children (<18 years) seem to rarely suffer from Long COVID and the few children who did get it, recover sooner from the symptoms in around 1-5 months duration (366).
The exact pathophysiology of this process is still under evaluation, but numerous theories have been proposed in this regard. One theory believes in the persistence of the virus in the tissues which could cause long-term stimulation of antigenic receptors and continued symptoms with a negative COVID-19 test swabbed from the nasopharynx. Several autopsies have shown the virus to persist in not only respiratory tissues but also kidneys, and intestines (367,368). This prolonged immune system stimulation gradually leads to immune dysregulation, immune exhaustion, and autoimmunity. Patients affected by severe COVID-19 are noted to have a hyperinflammatory cytokine response. This strongly supports the theory that chronic inflammation is ongoing even after recovery from the active infection which causes the symptoms of fatigue and arthralgias. COVID-19 also decreases the ACE-2 receptor expression which causes an imbalance in the renin-angiotensin system which alters the physiology (367). A study also noted that post-COVID-19 patients with symptoms had a lower nitrate level and a higher nitrite level compared to the uninfected group which could suggest the use of nitrates as a predictor for health status follow-up (369).
Reactivation of the virus is another concern in patients with Long COVID. It would be difficult to prove the origin of the virus – reactivation versus infection with a new strain. However, it does bring up the possibility of carriers. Given the symptom severity of Long COVID and other unknown possibilities, patients with Long COVID should be closely monitored. Below is a discussion about how Long COVID affects each organ system (370).
  • Myths associated with COVID-19
There has been a lot of mystery surrounding COVID-19 infection, especially the virus's origin leading to a myriad of myths. We have attempted to demystify some of the common myths associated with COVID-19.
COVID-19 virus was synthesized by laboratory manipulation of a related coronavirus - The genetic research showed evidence that COVID-19 is not derived from any known virus, so the possibility of laboratory manipulation would be highly unlikely. This information is also supported by WHO experts via a special commission investigation report. The existing theory about the origin of the virus is that it is an animal virus that got transmitted to humans, a process known as zoonosis (383).
Ibuprofen should be avoided in COVID-19 since it reacts with the virus - The role of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen in the immune response to COVID-19 is not clear. But it does reduce the production of inflammatory cytokines resulting in the complications associated with COVID-19 such as ARDS. Also, ACE-2 receptor is crucial in the pathogenesis of respiratory symptoms and the use of ibuprofen does not appear to increase the expression of ACE-2 receptors. Hence ibuprofen can be safely used to manage COVID-19 symptoms (384).
The virus is only 100 nm (0.1 mm) in size so filters and masks will not work - SARS-CoV-2 is transmitted in the form of respiratory droplets approximately 0.3-0.5 mm in size. A droplet contains respiratory secretions including water, protein, and salt among others. There is enough evidence to prove that masks can prevent virus spread from asymptomatic carriers. Along with masks, social distancing and hand hygiene help prevent virus transmission (385,386). It is also a myth that wearing a face mask would increase the level of carbon dioxide in the blood (387).
Ultraviolet lamps and sanitizer solutions should be used to disinfect hands - Using soap and water to wash hands is as effective as cleaning hands with an alcohol-based sanitizer. Hand hygiene along with social distancing helps reduce virus transmission. Using alcohol and chlorine-based sprays in high concentrations used for disinfection can be harmful if used on clothes or mucous membranes (386,387).
A positive PCR test is equivalent to an active infection - Patients with a positive PCR test with no active symptoms of COVID-19 can either be carriers or in a convalescent phase after a recent infection. Reinfection would be a possibility, but it is very unlikely. In a study on patients discharged from the hospital after COVID-19 infection, virus presence was noted in the sputum and feces for a few weeks after discharge (388).
Patients without symptoms cannot spread the infection - Most asymptomatic patients and those with mild symptoms can still spread the disease. Hence if the infection is suspected, there is a need to follow precautions such as hand hygiene and adequate social distancing (386).
The use of vitamins and minerals can prevent COVID-19 infection - Vitamins such as C and D, zinc, elderberry supplements, colloidal silver, and more have been thought to be beneficial for COVID-19 prevention and management of infection. CITRIS ALI trial showed no evidence of the administration of 50 mg/kg vitamin C for 4 days to alter the disease course or severity of acute respiratory failure (389). Vitamin D, if low, can cause acute respiratory infections with the risk of respiratory distress but there is no evidence of benefit in COVID-19 infection. Zinc inhibits virus multiplication and has a role in the treatment of the common cold. FDA declared colloidal silver as unsafe although it is an antibacterial and an antiviral agent. Elderberry has antiviral and immunomodulatory properties; a daily dose of 600 mg for 10 days can reduce the duration of cold symptoms. It needs to be cooked and improper cooking has risks of causing immunosuppression (390).
Hydroxychloroquine can prevent COVID-19 infection - The COVID-19 pandemic led to a rapid search for effective treatment options and drug repurposing appeared to be the fastest solution. Anti-malarial drugs such as chloroquine and hydroxychloroquine were noted to inhibit COVID-19 replication in-vitro. Hydroxychloroquine was found to be more potent than chloroquine. The studies were noted to have major limitations with short treatment periods with a high risk of bias. There is no definite proof to prove that hydroxychloroquine can be used for chemoprophylaxis (391,392).
The social distancing of 6 feet is always protective - A physical distance of at least 6 feet between two people is considered safe since it is assumed that respiratory droplets would not be able to travel the distance and infect other people. Recent studies show the ability of COVID-19 to aerosolize, meaning they can travel longer than 6 feet, but this is not the primary mode of infection transmission (393).
  • Conclusion
COVID-19 is a multisystem disease caused by a novel coronavirus, SARS-CoV-2. The pandemic has resulted in significant mortality, coupled with the loss of income leading to the global economic crisis. A variety of literature exists on various aspects of COVID-19 ranging from etiology to pathogenesis, organ manifestations, therapeutics, and vaccinations. The authors in this review strive to provide a detailed account of COVID-19 infection from various literature available, including the origins of COVID-19, pathogenesis, modes of infection, epidemiology, organ manifestations, therapeutics including vaccines, and infections in special circumstances.
Long-COVID remains a cause for concern given its prolonged sequelae, often leading to diminished quality of life for the patients. The impact of COVID-19 on the mental health of patients, and healthcare workers is not fully understood however, it must be noted that since the beginning of the pandemic, there has been a tremendous rise in psychiatric illnesses; new and worsening of a pre-existing disorder.
Over the last 3 years, despite various advancements in diagnosing infection, targeted therapeutic advancements are still in the research phase. Owing to the highly effective vaccines developed in record time, increasing immunity amongst the populations has significantly improved the death rates with ease on the overwhelmed health systems worldwide. Recently, the WHO declared COVID-19 to be no longer a global health emergency but cautioned the emergence of new variants leading to new cases and deaths.

References

  1. Fauci AS, Lane HC, Redfield RR. Covid-19 — Navigating the Uncharted. N Engl J Med. 2020 Mar 26;382(13):1268–9. [CrossRef]
  2. Phan DHB, Narayan PK. Country Responses and the Reaction of the Stock Market to COVID-19—a Preliminary Exposition. Emerg Mark Finance Trade. 2020 Aug 8;56(10):2138–50. [CrossRef]
  3. Statista [Internet]. [cited 2023 Apr 18]. Coronavirus (COVID-19) cases by country worldwide 2023. Available from: https://www.statista.com/statistics/1043366/novel-coronavirus-2019ncov-cases-worldwide-by-country/.
  4. Kaye AD, Okeagu CN, Pham AD, Silva RA, Hurley JJ, Arron BL, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Pract Res Clin Anaesthesiol. 2021 Oct 1;35(3):293–306. [CrossRef]
  5. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front Public Health [Internet]. 2021 [cited 2023 Apr 18];8. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2020.582932. [CrossRef]
  6. COVID - Coronavirus Statistics - Worldometer [Internet]. [cited 2023 Apr 18]. Available from: https://www.worldometers.info/coronavirus/.
  7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33. [CrossRef]
  8. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Res. 2018 Jan;149:58–74. [CrossRef]
  9. Haque SM, Ashwaq O, Sarief A, Azad John Mohamed AK. A comprehensive review about SARS-CoV-2. Future Virol. 2020 Sep;15(9):625–48. [CrossRef]
  10. Malik, YA. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020 Apr;42(1):3–11.
  11. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen HL, Chan MCW, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020 May;1(1):e10. [CrossRef]
  12. Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell. 2021 Aug 19;184(17):4380-4391.e14. [CrossRef]
  13. Pagani I, Ghezzi S, Alberti S, Poli G, Vicenzi E. Origin and evolution of SARS-CoV-2. Eur Phys J Plus. 2023;138(2):157.
  14. Virological [Internet]. 2021 [cited 2023 Apr 1]. Early appearance of two distinct genomic lineages of SARS-CoV-2 in different Wuhan wildlife markets suggests SARS-CoV-2 has a natural origin. Available from: https://virological.org/t/early-appearance-of-two-distinct-genomic-lineages-of-sars-cov-2-in-different-wuhan-wildlife-markets-suggests-sars-cov-2-has-a-natural-origin/691.
  15. Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing RW, et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Eurosurveillance. 2020 Jun 11;25(23):2001005.
  16. Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nat Commun. 2020 Dec 4;11:6231. [CrossRef]
  17. McAloose D, Laverack M, Wang L, Killian ML, Caserta LC, Yuan F, et al. From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo. mBio. 2020 Oct 13;11(5):e02220-20. [CrossRef]
  18. Graham RL, Baric RS. Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission. J Virol. 2010 Apr;84(7):3134–46. [CrossRef]
  19. Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 2021 Jan 29;538:88–91. [CrossRef]
  20. Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics. 2021 Jan 1;113(1, Part 2):1221–32. [CrossRef]
  21. WHO. Tracking SARS-CoV-2 variants [Internet]. [cited 2023 Mar 22]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
  22. CDC. Centers for Disease Control and Prevention. 2020 [cited 2023 Mar 22]. Coronavirus Disease 2019 (COVID-19) Variants of the Virus. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html.
  23. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. Eurosurveillance. 2021 Mar 4;26(9):2100133.
  24. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021 Apr 9;372(6538):eabg3055. [CrossRef]
  25. UK Govt. GOV.UK. [cited 2023 Mar 22]. NERVTAG paper on COVID-19 variant of concern B.1.1.7. Available from: https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117.
  26. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022 May 23;20(1):200. [CrossRef]
  27. Jacobs JL, Haidar G, Mellors JW. COVID-19: Challenges of Viral Variants. Annu Rev Med. 2023;74(1):31–53. [CrossRef]
  28. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 May 20;384(20):1885–98. [CrossRef]
  29. Duong, D. Duong D. Alpha, Beta, Delta, Gamma: What’s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021 Jul 12;193(27):E1059–60. [CrossRef]
  30. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, et al. Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clin Infect Dis. 2022 Jul 1;75(1):e1188–91. [CrossRef]
  31. Lin L, Liu Y, Tang X, He D. The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. Front Public Health [Internet]. 2021 [cited 2023 Mar 22];9. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2021.775224. [CrossRef]
  32. EU CDC. Threat Assessment Brief: Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA [Internet]. 2021 [cited 2023 Mar 22]. Available from: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants.
  33. Allen H, Vusirikala A, Flannagan J, Twohig KA, Zaidi A, Chudasama D, et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study. Lancet Reg Health - Eur. 2022 Jan 1;12:100252. [CrossRef]
  34. Bolze A, Luo S, White S, Cirulli ET, Wyman D, Rossi AD, et al. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. Cell Rep Med [Internet]. 2022 Mar 15 [cited 2023 Mar 22];3(3). Available from: https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(22)00071-4.
  35. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022 Jan 1;22(1):35–42. [CrossRef]
  36. Delta variant : what we know about the science [Internet]. [cited 2023 May 3]. Available from: https://stacks.cdc.gov/view/cdc/108671.
  37. Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res. 2022 Jun 1;209:112816. [CrossRef]
  38. Arora S, Grover V, Saluja P, Algarni YA, Saquib SA, Asif SM, et al. Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms. 2022 Feb;10(2):451. [CrossRef]
  39. Lubin JH, Markosian C, Balamurugan D, Pasqualini R, Arap W, Burley SK, et al. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces [Internet]. bioRxiv; 2021 [cited 2023 Mar 22]. p. 2021.12.12.472313. Available from: https://www.biorxiv.org/content/10.1101/2021.12.12.472313v1.
  40. Christie, B. Christie B. Covid-19: Early studies give hope omicron is milder than other variants. BMJ. 2021 Dec 23;375:n3144. [CrossRef]
  41. Hui KPY, Ho JCW, Cheung M chun, Ng K chun, Ching RHH, Lai K ling, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022 Mar;603(7902):715–20. [CrossRef]
  42. Parums DV. Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread. Med Sci Monit [Internet]. 2023 Feb 1 [cited 2023 Mar 22];29. Available from: https://medscimonit.com/abstract/full/idArt/939580.
  43. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020 Apr;26(4):450–2. [CrossRef]
  44. Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, et al. The origins of SARS-CoV-2: A critical review. Cell. 2021 Sep;184(19):4848–56.
  45. NCBI [Internet]. [cited 2023 May 2]. News: What does the science say about the.. (NPR News) - Behind the headlines - NLM. Available from: https://www.ncbi.nlm.nih.gov/search/research-news/18331.
  46. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020 Mar 2;5(1):6. [CrossRef]
  47. Team TNCPERE. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Wkly. 2020 Feb 1;2(8):113–22.
  48. Worobey M, Levy JI, Malpica Serrano L, Crits-Christoph A, Pekar JE, Goldstein SA, et al. The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. Science. 2022 Aug 26;377(6609):951–9. [CrossRef]
  49. Mallapaty S. WHO abandons plans for crucial second phase of COVID-origins investigation. Nature [Internet]. 2023 Feb 14 [cited 2023 May 2]; Available from: https://www.nature.com/articles/d41586-023-00283-y. [CrossRef]
  50. WHO-convened global study of origins of SARS-CoV-2: China Part [Internet]. [cited 2023 May 2]. Available from: https://www.who.int/publications-detail-redirect/who-convened-global-study-of-origins-of-sars-cov-2-china-part.
  51. A Lab Leak in China Most Likely Origin of Covid Pandemic, Energy Department Says - WSJ [Internet]. [cited 2023 May 2]. Available from: https://www.wsj.com/articles/covid-origin-china-lab-leak-807b7b0a.
  52. Richards F, Kodjamanova P, Chen X, Li N, Atanasov P, Bennetts L, et al. Economic Burden of COVID-19: A Systematic Review. Clin Outcomes Res CEOR. 2022;14:293–307. [CrossRef]
  53. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021 Feb 12;39(7):1157–64. [CrossRef]
  54. Athanasakis K, Nomikos N, Souliotis K, Kyriopoulos J. PNS21 From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic. Value Health. 2020 Dec 1;23:S647. [CrossRef]
  55. Miethke-Morais A, Cassenote A, Piva H, Tokunaga E, Cobello V, Rodrigues Gonçalves FA, et al. COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2021;25(4):101609. [CrossRef]
  56. Miles DK, Stedman M, Heald AH. “Stay at Home, Protect the National Health Service, Save Lives”: A cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract. 2021;75(3):e13674. [CrossRef]
  57. Hafner M, Yerushalmi E, Fays C, Dufresne E, Van Stolk C. COVID-19 and the cost of vaccine nationalism [Internet]. RAND Corporation; 2020 [cited 2023 May 2]. Available from: https://www.rand.org/pubs/research_reports/RRA769-1.html.
  58. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States | Health Affairs [Internet]. [cited 2023 May 2]. Available from: https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.00426. [CrossRef]
  59. Nakhaei K, Jalilian H, Arab-Zozani M, Heydari S, Torkzadeh L, Taji M. Direct and indirect cost of COVID-19 patients in Iran. Health Policy Technol. 2021 Dec;10(4):100572. [CrossRef]
  60. Gedik H. The cost analysis of inpatients with COVID-19. Acta Medica Mediterr. 2020 Dec 1;(6):3289–92.
  61. Yigezu A, Zewdie SA, Mirkuzie AH, Abera A, Hailu A, Agachew M, et al. Cost-analysis of COVID-19 sample collection, diagnosis, and contact tracing in low resource setting: The case of Addis Ababa, Ethiopia. PLOS ONE. 2022 Jun 9;17(6):e0269458. [CrossRef]
  62. Hashmi P, Fahad S, Naqi Khan H, Zahid M, Sadruddin A, Noordin S. Covid-19 pandemic: Economic burden on patients with musculoskeletal injuries in a tertiary care hospital of LMIC; retrospective cross sectional study. Ann Med Surg 2012. 2020 Dec;60:5–8. [CrossRef]
  63. US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines - PMC [Internet]. [cited 2023 Jun 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426978/.
  64. Nonvignon J, Owusu R, Asare B, Adjagba A, Aun YW, Yeung KHT, et al. Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool. Vaccine. 2022 Mar 15;40(12):1879–87. [CrossRef]
  65. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430–6. [CrossRef]
  66. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021 Jan;31(1):1–10. [CrossRef]
  67. CDC. Centers for Disease Control and Prevention. 2020 [cited 2023 May 2]. COVID Data Tracker. Available from: https://covid.cdc.gov/covid-data-tracker.
  68. Centers for Disease Control and Prevention [Internet]. 2020 [cited 2023 May 3]. Coronavirus Disease 2019 (COVID-19). Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html.
  69. Carethers, JM. Carethers JM. Insights into disparities observed with COVID-19. J Intern Med. 2021 Apr;289(4):463–73. [CrossRef]
  70. Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A, et al. Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger? Neuroendocrinology. 2021;111(11):1066–85. [CrossRef]
  71. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. Ann Intern Med. 2021 Mar;174(3):362–73. [CrossRef]
  72. Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-analysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147. [CrossRef]
  73. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016 Jun 1;24(6):490–502. [CrossRef]
  74. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25;324(8):782–93. [CrossRef]
  75. Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021 Nov;19(11):685–700. [CrossRef]
  76. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022 May;20(5):270–84. [CrossRef]
  77. Marik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol. 2021 Sep 26;35:20587384211048024. [CrossRef]
  78. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant. 2020 May 1;39(5):405–7. [CrossRef]
  79. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389–91. [CrossRef]
  80. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020 Jul;75(7):1564–81. [CrossRef]
  81. Cascella M, Montomoli J, Bellini V, Bignami E. Evaluating the Feasibility of ChatGPT in Healthcare: An Analysis of Multiple Clinical and Research Scenarios. J Med Syst. 2023;47(1):33. [CrossRef]
  82. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120–8. [CrossRef]
  83. Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Apr;34(2):327–31.
  84. Kornowski R, Witberg G. Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. Open Heart. 2022 Mar 1;9(1):e001957. [CrossRef]
  85. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020 Mar 28;395(10229):1033–4. [CrossRef]
  86. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological Study of the 2019 Novel Coronavirus Disease (COVID-19) through Post-Mortem Core Biopsies. 2020 Mar 20 [cited 2023 Mar 22]; Available from: https://www.preprints.org/manuscript/202003.0311/v1.
  87. Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020 Nov;33(11):2156–68. [CrossRef]
  88. Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Oct;1(6):e245–53. [CrossRef]
  89. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May 1;158(6):1831-1833.e3.
  90. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul;98(1):219–27. [CrossRef]
  91. Duarte-Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes-Gouvêa MS, dos Santos ABG, et al. Testicular pathology in fatal COVID-19: A descriptive autopsy study. Andrology. 2022 Jan;10(1):13–23. [CrossRef]
  92. Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. Neuropathological Features of Covid-19. N Engl J Med. 2020 Jun 12;NEJMc2019373. [CrossRef]
  93. Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020 Jun 12;7(5):2440–7. [CrossRef]
  94. Gianotti R, Zerbi P, Dodiuk-Gad RP. Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Dermatol Sci. 2020 May;98(2):141–3. [CrossRef]
  95. Cazzato, G. Cazzato G. Cutaneous Manifestations of SARS-CoV-2, Cutaneous Adverse Reactions to Vaccines Anti-SARS-CoV-2 and Clinical/Dermoscopical Findings: Where We Are and Where We Will Go. Vaccines. 2023 Jan 10;11(1):152. [CrossRef]
  96. Kumar P, Radha G, Muthukrishnan M, Chandrasekaran B, Subbiah P, Raman J. Cutaneous Manifestations Associated with COVID-19 Infection in a COVID-Designated Hospital in North Chennai – A Descriptive Cross-Sectional Study. Indian Dermatol Online J. 2022 Dec 29;14(1):67–71. [CrossRef]
  97. Rajan M B, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Nov;59(11):1358–70. [CrossRef]
  98. Afrisham R, Jadidi Y, Davoudi M, Moayedi K, Karami S, Sadegh-Nejadi S, et al. Renal, Cardiac, Neurological, Cutaneous and Coagulopathic Long-term Manifestations of COVID-19 after Recovery; A review. Epidemiol Infect. 2022 Sep 21;1–29. [CrossRef]
  99. Lin L, Chen Y, Han D, Yang A, Wang AY, Qi W. Cardiorenal Syndrome in COVID-19 Patients: A Systematic Review. Front Cardiovasc Med. 2022 Jun 28;9:915533. [CrossRef]
  100. Crosier R, Kafil TS, Paterson DI. Imaging for Cardiovascular Complications of COVID-19: Cardiac Manifestations in Context. Can J Cardiol. 2023 Jan 31;S0828-282X(23)00068-5. [CrossRef]
  101. Dommaraju S, Avula S, Buch T, Kela K, Babic M. Brugada pattern unmasked by covid19 infection complicated by cardiogenic shock. J Am Coll Cardiol. 2021 May 11;77(18_Supplement_1):2020–2020. [CrossRef]
  102. Dubey L, Dorosh O, Dubey N, Doan S, Kozishkurt O, Duzenko O, et al. COVID-19-induced coagulopathy: Experience, achievements, prospects. Cardiol J. 2023 Jan 2; [CrossRef]
  103. Kobusiak-Prokopowicz M, Fułek K, Fułek M, Kaaz K, Mysiak A, Kurpas D, et al. Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19. Cells. 2022 Dec 1;11(23):3882. [CrossRef]
  104. Molina G, Contreras R, Coombes K, Walgamage T, Perozo MA, DesBiens MT. Hemophagocytic Lymphohistiocytosis Following COVID-19 Infection. Cureus. 15(1):e34307. [CrossRef]
  105. Iskander P, Zheng J, Zaidi SMH, Iskander A. A coagulopathic conundrum of COVID-19. Univ Tor Med J [Internet]. 2023 Feb 28 [cited 2023 Jun 27];100(1). Available from: https://jps.library.utoronto.ca/index.php/utmj/article/view/39018.
  106. Kalita P, Dey B, Mishra J, Tiewsoh I, Raphael V. Immunoglobulin A Nephropathy in a SARS-CoV-2-Positive Patient With Coexistent Metabolic Syndrome. Cureus. 14(9):e28719. [CrossRef]
  107. Malgaj Vrečko M, Aleš Rigler A, Večerić-Haler Ž. Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review. Int J Mol Sci. 2022 Sep 25;23(19):11307. [CrossRef]
  108. Janbazi Roudsari H, Negaresh M, Shirzadeh V, Mohammadzadeh Germi B, Mirzaei A. Renal vein thrombosis after COVID-19: A case report. Clin Case Rep. 2022 Dec 26;10(12):e6778. [CrossRef]
  109. Flores VAG, Chicano S, Resontoc LP, Aragon EE. Diffuse proliferative glomerulonephritis in a patient with COVID-19 infection. BMJ Case Rep CP. 2023 Jan 1;16(1):e251962. [CrossRef]
  110. El-Kassas M, Alboraie M, Elbadry M, El Sheemy R, Abdellah M, Afify S, et al. Non-pulmonary involvement in COVID-19: A systemic disease rather than a pure respiratory infection. World J Clin Cases. 2023 Jan 26;11(3):493–505. [CrossRef]
  111. Radovic S, Meng W, Chen L, Paniz Mondolfi AE, Bryce C, Grimes Z, et al. SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients. J Med Virol. 2023 Feb;95(2):e28566. [CrossRef]
  112. Jayadi, Airlangga PS, Kusuma E, Waloejo CS, Salinding A, Lestari P. Correlation between serum surfactant protein-D level with respiratory compliance and acute respiratory distress syndrome in critically ill COVID-19 Patients: A retrospective observational study. Int J Crit Illn Inj Sci. 2022;12(4):204–10. [CrossRef]
  113. Vangara A, Rahmlow TH, Gullapalli D, Kommineni SS, Haroon M, Ganti SS, et al. COVID-19 and Cavitary Lesion in Lung. Cureus [Internet]. 2023 Jan 23 [cited 2023 Jun 28];15(1). Available from: https://www.cureus.com/articles/126856-covid-19-and-cavitary-lesion-in-lung.
  114. Ekanem E, Podder S, Donthi N, Bakhshi H, Stodghill J, Khandhar S, et al. Spontaneous pneumothorax: An emerging complication of COVID-19 pneumonia. Heart Lung J Crit Care. 2021;50(3):437–40. [CrossRef]
  115. Ramalingam S, Arora H, Gunasekaran K, Muruganandam M, Nagaraju S. A Unique Case of Spontaneous Pneumomediastinum in a Patient With COVID-19 and Influenza Coinfection. J Investig Med High Impact Case Rep. 2021;9:23247096211016228. [CrossRef]
  116. Del Nonno F, Colombo D, Nardacci R, Falasca L. Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization. Thromb J. 2021 Jan 6;19(1):1. [CrossRef]
  117. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020 Jul 14;142(2):184–6. [CrossRef]
  118. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100639. [CrossRef]
  119. Aquino-Matus J, Uribe M, Chavez-Tapia N. COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases—A Concise Review. Trop Med Infect Dis. 2022 Aug 16;7(8):187. [CrossRef]
  120. Schmulson M, Dávalos MF, Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19. Rev Gastroenterol Mex Engl. 2020;85(3):282–7. [CrossRef]
  121. Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020 Jun 1;69(6):1141–3. [CrossRef]
  122. Groff A, Kavanaugh M, Ramgobin D, McClafferty B, Aggarwal CS, Golamari R, et al. Gastrointestinal Manifestations of COVID-19: A Review of What We Know. Ochsner J. 2021;21(2):177–80. [CrossRef]
  123. Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol. 2020 Jul;115(7):1003–6.
  124. Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, Pontas C, Tsoukalas N, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020 Aug 21;26(31):4579–88. [CrossRef]
  125. Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol. 2021 Jul 28;27(28):4504–35. [CrossRef]
  126. Keshavarz P, Rafiee F, Kavandi H, Goudarzi S, Heidari F, Gholamrezanezhad A. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin Imaging. 2021 May;73:86–95. [CrossRef]
  127. Uhlenhopp DJ, Ramachandran R, Then E, Parvataneni S, Grantham T, Gaduputi V. COVID-19-Associated Ischemic Colitis: A Rare Manifestation of COVID-19 Infection—Case Report and Review. J Investig Med High Impact Case Rep. 2022 Mar 28;10:23247096211065624. [CrossRef]
  128. Kukla M, Skonieczna-Żydecka K, Kotfis K, Maciejewska D, Łoniewski I, Lara LuisF, et al. COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature. J Clin Med. 2020 May 11;9(5):1420. [CrossRef]
  129. Ferreira RJO, Welsing PMJ, Jacobs JWG, Gossec L, Ndosi M, Machado PM, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Ann Rheum Dis. 2021 Mar;80(3):293–303. [CrossRef]
  130. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int Off J Int Assoc Study Liver. 2021 Jan;41(1):20–32. [CrossRef]
  131. Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, et al. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021 Jan;55(1):1–11. [CrossRef]
  132. Lagana SM, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol Off J U S Can Acad Pathol Inc. 2020 Nov;33(11):2147–55. [CrossRef]
  133. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver Injury and Failure in Critical Illness. Hepatol Baltim Md. 2019 Dec;70(6):2204–15. [CrossRef]
  134. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 May 1;8(5):416–27. [CrossRef]
  135. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683–90. [CrossRef]
  136. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020 Oct;50(3):587–95. [CrossRef]
  137. Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bnà C, et al. Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. 2020 Aug;267(8):2185–92. [CrossRef]
  138. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020 May 14;382(20):e60. [CrossRef]
  139. Vogrig A, Gigli GL, Bnà C, Morassi M. Stroke in patients with COVID-19: Clinical and neuroimaging characteristics. Neurosci Lett. 2021 Jan 19;743:135564. [CrossRef]
  140. Xie Z, Hui H, Zhao Z, Yu W, Wu R, Zhu Y, et al. Nervous system manifestations related to COVID-19 and their possible mechanisms. Brain Res Bull. 2022 Sep;187:63–74. [CrossRef]
  141. Kirschenbaum D, Imbach LL, Rushing EJ, Frauenknecht KBM, Gascho D, Ineichen BV, et al. Intracerebral endotheliitis and microbleeds are neuropathological features of COVID-19. Neuropathol Appl Neurobiol. 2021 Apr;47(3):454–9. [CrossRef]
  142. Kow CS, Zaihan AF, Hasan SS. Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis. J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105222. [CrossRef]
  143. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost JTH. 2020 May;18(5):1023–6. [CrossRef]
  144. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, et al. Targeting the Degradation of Angiotensin II with Recombinant ACE2: Prevention of Angiotensin II-dependent Hypertension. Hypertension. 2010 Jan;55(1):90–8. [CrossRef]
  145. Soltani Zangbar H, Gorji A, Ghadiri T. A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View. Mol Neurobiol. 2021 Feb;58(2):536–49. [CrossRef]
  146. Virhammar J, Kumlien E, Fällmar D, Frithiof R, Jackmann S, Sköld MK, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020 Sep 8;95(10):445–9. [CrossRef]
  147. Radmanesh A, Derman A, Ishida K. COVID-19-associated delayed posthypoxic necrotizing leukoencephalopathy. J Neurol Sci. 2020 Aug 15;415:116945. [CrossRef]
  148. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020 Aug;296(2):E119–20. [CrossRef]
  149. Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun. 2020 Jul;87:177–8. [CrossRef]
  150. Ramalingam S, Arora H, Lewis S, Gunasekaran K, Muruganandam M, Nagaraju S, et al. COVID-19 vaccine-induced cellulitis and myositis. Cleve Clin J Med. 2021 Dec 2;88(12):648–50. [CrossRef]
  151. Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med Sci Monit Int Med J Exp Clin Res. 2020 Nov 1;26:e928996. [CrossRef]
  152. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure. 2020 May;78:109–12. [CrossRef]
  153. Hepburn M, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A, et al. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? Neurocrit Care. 2021 Feb;34(1):139–43. [CrossRef]
  154. Scullen T, Keen J, Mathkour M, Dumont AS, Kahn L. Coronavirus 2019 (COVID-19)–Associated Encephalopathies and Cerebrovascular Disease: The New Orleans Experience. World Neurosurg. 2020 Sep;141:e437–46. [CrossRef]
  155. Shehata GA, Lord KC, Grudzinski MC, Elsayed M, Abdelnaby R, Elshabrawy HA. Neurological Complications of COVID-19: Underlying Mechanisms and Management. Int J Mol Sci. 2021 Apr 15;22(8):4081. [CrossRef]
  156. Bo HX, Li W, Yang Y, Wang Y, Zhang Q, Cheung T, et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol Med. 2021 Apr;51(6):1052–3. [CrossRef]
  157. De Boni RB, Balanzá-Martínez V, Mota JC, Cardoso TDA, Ballester P, Atienza-Carbonell B, et al. Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic. J Med Internet Res. 2020 Oct 30;22(10):e22835. [CrossRef]
  158. Czeisler MÉ, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049–57. [CrossRef]
  159. Leven Y, Bösel J. Neurological manifestations of COVID-19 - an approach to categories of pathology. Neurol Res Pract. 2021 Jul 26;3(1):39. [CrossRef]
  160. Esmaeili M, Abdi F, Shafiee G, Asayesh H, Abdar ZE, Baygi F, et al. Olfactory and Gustatory Dysfunction in 2019 Novel Coronavirus: An Updated Systematic Review and Meta-analysis. Int J Prev Med. 2021 Dec 14;12:170. [CrossRef]
  161. Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. JAMA Otolaryngol-- Head Neck Surg. 2020 Aug 1;146(8):729–32. [CrossRef]
  162. Fodoulian L, Tuberosa J, Rossier D, Boillat M, Kan C, Pauli V, et al. SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain. iScience. 2020 Nov 25;23(12):101839.
  163. Xu W, Sunavala-Dossabhoy G, Spielman AI. Chemosensory loss in COVID-19. Oral Dis. 2022 Nov;28 Suppl 2:2337–46. [CrossRef]
  164. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry. 2021 Dec;27(6):582–603. [CrossRef]
  165. Danesh-Meyer HV, McGhee CNJ. Implications of COVID-19 for Ophthalmologists. Am J Ophthalmol. 2021 Mar;223:108–18. [CrossRef]
  166. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol J Can Ophtalmol. 2020 Aug;55(4):e125–9. [CrossRef]
  167. Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. Am J Ophthalmol Case Rep. 2020 May 6;19:100735. [CrossRef]
  168. Update on overview of ocular manifestations of COVID-19 - PMC [Internet]. [cited 2023 May 3]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513125/.
  169. Invernizzi A, Pellegrini M, Messenio D, Cereda M, Olivieri P, Brambilla AM, et al. Impending Central Retinal Vein Occlusion in a Patient with Coronavirus Disease 2019 (COVID-19). Ocul Immunol Inflamm. 2020 Nov 16;28(8):1290–2. [CrossRef]
  170. Walinjkar JA, Makhija SC, Sharma HR, Morekar SR, Natarajan S. Central retinal vein occlusion with COVID-19 infection as the presumptive etiology. Indian J Ophthalmol. 2020 Nov;68(11):2572–4. [CrossRef]
  171. Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: A novel entity. Indian J Ophthalmol. 2020 Oct;68(10):2291–3. [CrossRef]
  172. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021 Apr;69(4):1002–4. [CrossRef]
  173. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol. 2021 Feb;69(2):244–52. [CrossRef]
  174. Brix TH, Hegedüs L, Hallas J, Lund LC. Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol. 2021 Apr;9(4):197–9.
  175. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. Thyroid®. 2021 Jan;31(1):8–11. [CrossRef]
  176. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3′,5′-Triiodothyronine (rT3) and 3,5,3′-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. J Clin Endocrinol Metab. 2005 Aug 1;90(8):4559–65. [CrossRef]
  177. Chen Y, Li X, Dai Y, Zhang J. The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis. Front Endocrinol. 2021;12:779692. [CrossRef]
  178. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, et al. Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild-to-moderate severity. Clin Endocrinol (Oxf). 2021 Sep;95(3):469–77. [CrossRef]
  179. Clarke SA, Phylactou M, Patel B, Mills EG, Muzi B, Izzi-Engbeaya C, et al. Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. J Clin Endocrinol Metab. 2021 Jul 13;106(8):2208–20. [CrossRef]
  180. Barkhoudarian G, Kelly DF. Pituitary Apoplexy. Neurosurg Clin N Am. 2019 Oct;30(4):457–63.
  181. Chigr F, Merzouki M, Najimi M. Autonomic Brain Centers and Pathophysiology of COVID-19. ACS Chem Neurosci. 2020 Jun 3;11(11):1520–2. [CrossRef]
  182. Christ-Crain M, Hoorn EJ, Sherlock M, Thompson CJ, Wass JAH. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia. Eur J Endocrinol. 2020 Jul;183(1):G9–15.
  183. Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF. Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am. 2020 Sep;49(3):553–64. [CrossRef]
  184. Leyendecker P, Ritter S, Riou M, Wackenthaler A, Meziani F, Roy C, et al. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol. 2021;31(2):895–900. [CrossRef]
  185. Amiri-Dashatan N, Koushki M, Parsamanesh N, Chiti H. Serum cortisol concentration and COVID-19 severity: a systematic review and meta-analysis. J Investig Med Off Publ Am Fed Clin Res. 2022 Mar;70(3):766–72. [CrossRef]
  186. Tan T, Khoo B, Mills EG, Phylactou M, Patel B, Eng PC, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020 Aug;8(8):659–60. [CrossRef]
  187. Kanczkowski W, Evert K, Stadtmüller M, Haberecker M, Laks L, Chen LS, et al. COVID-19 targets human adrenal glands. Lancet Diabetes Endocrinol. 2022 Jan;10(1):13–6. [CrossRef]
  188. Tresoldi AS, Sumilo D, Perrins M, Toulis KA, Prete A, Reddy N, et al. Increased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2020 Feb 1;105(2):418–29. [CrossRef]
  189. Quinkler M, Ekman B, Zhang P, Isidori AM, Murray RD, EU-AIR Investigators. Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations. Clin Endocrinol (Oxf). 2018 Jul;89(1):30–5. [CrossRef]
  190. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020 Dec 9;11(1):6317. [CrossRef]
  191. Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online. 2021 Jan;42(1):260–7. [CrossRef]
  192. F C, S Z, Z D, L H, C L, Q G, et al. Effects of COVID-19 and mRNA vaccines on human fertility. Hum Reprod Oxf Engl [Internet]. 2021 Dec 27 [cited 2023 Jun 26];37(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34734259/.
  193. Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA Netw Open. 2020 May 7;3(5):e208292. [CrossRef]
  194. Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, et al. Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19. JAMA Netw Open. 2021 May 25;4(5):e2111398. [CrossRef]
  195. Gagliardi L, Bertacca C, Centenari C, Merusi I, Parolo E, Ragazzo V, et al. Orchiepididymitis in a Boy With COVID-19. Pediatr Infect Dis J. 2020 Aug;39(8):e200–2. [CrossRef]
  196. Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the Endocrine System: A Mini-review. Endocrinology. 2022 Jan 1;163(1):bqab203. [CrossRef]
  197. Chen L, Huang X, Yi Z, Deng Q, Jiang N, Feng C, et al. Ultrasound Imaging Findings of Acute Testicular Infection in Patients With Coronavirus Disease 2019: A Single-Center-Based Study in Wuhan, China. J Ultrasound Med Off J Am Inst Ultrasound Med. 2021 Sep;40(9):1787–94. [CrossRef]
  198. Ruan Y, Hu B, Liu Z, Liu K, Jiang H, Li H, et al. No detection of SARS-CoV-2 from urine, expressed prostatic secretions, and semen in 74 recovered COVID-19 male patients: A perspective and urogenital evaluation. Andrology. 2021 Jan;9(1):99–106. [CrossRef]
  199. Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022 Feb;226(2):177–86. [CrossRef]
  200. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021 Aug 1;175(8):817–26.
  201. Chmielewska B, Barratt I, Townsend R, Kalafat E, Meulen J van der, Gurol-Urganci I, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. Lancet Glob Health. 2021 Jun 1;9(6):e759–72. [CrossRef]
  202. Fenizia C, Biasin M, Cetin I, Vergani P, Mileto D, Spinillo A, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nat Commun. 2020 Oct 12;11(1):5128. [CrossRef]
  203. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010 Sep;47(3):193–9. [CrossRef]
  204. Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020 Jun;164:108166. [CrossRef]
  205. Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021 Feb;3(2):149–65. [CrossRef]
  206. Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, et al. Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metab. 2020 Dec 1;32(6):1041-1051.e6. [CrossRef]
  207. Marchand L, Pecquet M, Luyton C. Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2020;57(10):1265–6. [CrossRef]
  208. Hollstein T, Schulte DM, Schulz J, Glück A, Ziegler AG, Bonifacio E, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab. 2020 Oct;2(10):1021–4. [CrossRef]
  209. Armeni E, Aziz U, Qamar S, Nasir S, Nethaji C, Negus R, et al. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol. 2020 Aug;8(8):660–3. [CrossRef]
  210. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020 Oct;22(10):1935–41. [CrossRef]
  211. Anderson MR, Shashaty MGS. Impact of Obesity in Critical Illness. Chest. 2021 Dec;160(6):2135–45. [CrossRef]
  212. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021 Dec;600(7889):472–7.
  213. Földi M, Farkas N, Kiss S, Dembrovszky F, Szakács Z, Balaskó M, et al. Visceral Adiposity Elevates the Risk of Critical Condition in COVID-19: A Systematic Review and Meta-Analysis. Obes Silver Spring Md. 2021 Mar;29(3):521–8. [CrossRef]
  214. Oguz SH, Koca M, Yildiz BO. Aging versus youth: Endocrine aspects of vulnerability for COVID-19. Rev Endocr Metab Disord. 2022;23(2):185. [CrossRef]
  215. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa [Internet]. medRxiv; 2021 [cited 2023 May 3]. p. 2021.12.21.21268116. Available from: https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1.
  216. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California [Internet]. medRxiv; 2022 [cited 2023 May 3]. p. 2022.01.11.22269045. Available from: https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1.
  217. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR [Internet]. [cited 2023 May 3]. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e2.htm?s_cid=mm7104e2_w.%20https://doi.org/10.15585/mmwr.mm7104e2. [CrossRef]
  218. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2022 Mar;116:38–42. [CrossRef]
  219. Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. 2021 Dec 29;rs.3.rs-1211792.
  220. León TM. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2023 May 3];71. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e1.htm.
  221. publisher, E. publisher E. World Health Organization - Regional Office for the Eastern Mediterranean. [cited 2023 Jun 29]. Information note on new COVID-19 Omicron subvariant XBB.1.5. Available from: http://www.emro.who.int/media/news/information-note-on-new-covid-19-omicron-subvariant-xbb15.html.
  222. Mahase, E. Mahase E. Covid-19: What do we know about XBB.1.5 and should we be worried? BMJ. 2023 Jan 19;380:p153. [CrossRef]
  223. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Apr 19;71(16):2249–51. [CrossRef]
  224. CDC. Centers for Disease Control and Prevention. 2020 [cited 2023 Apr 17]. Healthcare Workers. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html.
  225. NIH COVID-19 Research [Internet]. [cited 2023 May 3]. Home. Available from: https://covid19.nih.gov/homepage.
  226. EMA. European Medicines Agency. 2021 [cited 2023 May 3]. EMA and Health Canada publish clinical data used to support their authorisations of the Moderna COVID-19 vaccine. Available from: https://www.ema.europa.eu/en/news/ema-health-canada-publish-clinical-data-used-support-their-authorisations-moderna-covid-19-vaccine.
  227. ClinicalStudyDataRequest.com [Internet]. [cited 2023 May 4]. Available from: https://www.clinicalstudydatarequest.com/.
  228. The YODA Project | Trials By Generic Name [Internet]. [cited 2023 May 4]. Available from: https://yoda.yale.edu/browsetrials/generic-name.
  229. Home – GREI - Vivli [Internet]. [cited 2023 May 3]. Available from: https://vivli.org/. https://vivli.org/.
  230. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021 Apr;20(4):254–5. [CrossRef]
  231. Palm ME, Lindsell CJ, Selker HP. Sharing data among clinical trials of therapeutics in COVID-19: Barriers and facilitators to collaborating in a crisis. J Clin Transl Sci. 6(1):e52. [CrossRef]
  232. Janiaud P, Hemkens LG, Ioannidis JPA. Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently? Can J Cardiol. 2021 Sep;37(9):1353–64.
  233. Negi K, Agarwal M, Pahuja I, Bhardwaj B, Rawat M, Bhaskar A, et al. Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. Oxf Open Immunol. 2023 Jan 1;4(1):iqad001. [CrossRef]
  234. Recovery protocol [Internet]. [cited 2023 May 3]. Available from: https://www.recoverytrial.net/files/recovery-protocol-v12-1-2020-12-16.pdf.
  235. Demotes-Mainard J. [ECRIN (European clinical research infrastructures network), a pan-European infrastructure for clinical research]. Bull Acad Natl Med. 2010 Dec;194(9):1683–94.
  236. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020 Oct 24;396(10259):1345–52. [CrossRef]
  237. National Institute of Allergy and Infectious Diseases (NIAID). A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults [Internet]. clinicaltrials.gov; 2022 Mar [cited 2023 May 2]. Report No.: NCT04280705. Available from: https://clinicaltrials.gov/ct2/show/NCT04280705.
  238. Hospital do Coracao. An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients [Internet]. clinicaltrials.gov; 2022 Apr [cited 2023 May 2]. Report No.: results/NCT04322123. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04322123.
  239. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. The Lancet. 2022 May 21;399(10339):1941–53. [CrossRef]
  240. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693–704. [CrossRef]
  241. INSPIRATION Investigators, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 Apr 27;325(16):1620–30.
  242. Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021 Nov 1;47(11):1258–70. [CrossRef]
  243. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777–89. [CrossRef]
  244. Barbaro RP, MacLaren G, Boonstra PS, Combes A, Agerstrand C, Annich G, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. The Lancet. 2021 Oct;398(10307):1230–8. [CrossRef]
  245. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 Feb 1;22(2):209–21. [CrossRef]
  246. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Lond Engl. 2022 Jan 8;399(10320):143–51. [CrossRef]
  247. Fralick M, Colacci M, Munshi L, Venus K, Fidler L, Hussein H, et al. Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE). BMJ. 2022 Mar 23;376:e068585. [CrossRef]
  248. Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, et al. An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 [Internet]. medRxiv; 2021 [cited 2023 May 8]. p. 2021.08.02.21261379. Available from: https://www.medrxiv.org/content/10.1101/2021.08.02.21261379v1.
  249. Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022 May 5;386(18):1721–31. [CrossRef]
  250. Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, et al. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022 Dec;10(12):1169–77. [CrossRef]
  251. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397–408. [CrossRef]
  252. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar;28(3):583–90. [CrossRef]
  253. Writing Committee for the REMAP-CAP Investigators. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2023 Jan 3;329(1):39–51.
  254. Schwartz KL, Wang J, Tadrous M, Langford BJ, Daneman N, Leung V, et al. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19. CMAJ Can Med Assoc J J Assoc Medicale Can. 2023 Feb 13;195(6):E220–6. [CrossRef]
  255. Dougan M, Azizad M, Chen P, Feldman B, Frieman M, Igbinadolor A, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 [Internet]. medRxiv; 2022 [cited 2023 Mar 2]. p. 2022.03.10.22272100. Available from: https://www.medrxiv.org/content/10.1101/2022.03.10.22272100v1.
  256. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Dec 2;385(23):e81. [CrossRef]
  257. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15. [CrossRef]
  258. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl. 2021 Jan 9;397(10269):99–111. [CrossRef]
  259. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–16.
  260. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187–201. [CrossRef]
  261. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531–43. [CrossRef]
  262. Kwan AC, Ebinger JE, Botting P, Navarrette J, Claggett B, Cheng S. Association of COVID-19 Vaccination With Risk for Incident Diabetes After COVID-19 Infection. JAMA Netw Open. 2023 Feb 14;6(2):e2255965. [CrossRef]
  263. Robinson PC, Liew DFL, Tanner HL, Grainger JR, Dwek RA, Reisler RB, et al. COVID-19 therapeutics: Challenges and directions for the future. Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2119893119. [CrossRef]
  264. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–71. [CrossRef]
  265. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020 Nov 5;383(19):1813–26. [CrossRef]
  266. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022 Jan 27;386(4):305–15. [CrossRef]
  267. Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021 Dec 24;374(6575):1586–93. [CrossRef]
  268. The Food and Drug Administration (FDA). FDA Paxlovid [Internet]. [cited 2023 Mar 2]. Available from: https://www.fda.gov/media/155050/download.
  269. Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. [CrossRef]
  270. Benaicha K, Khenhrani RR, Veer M, Devi S, Shahbaz U, Salah QM, et al. Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis. Cureus [Internet]. 2023 May 5 [cited 2023 Jun 27]; Available from: https://www.cureus.com/articles/155447-efficacy-of-molnupiravir-for-the-treatment-of-mild-or-moderate-covid-19-in-adults-a-meta-analysis.
  271. Alavi Darazam I, Hatami F, Mahdi Rabiei M, Amin Pourhoseingholi M, Shabani M, Shokouhi S, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. Int Immunopharmacol. 2021 Oct;99:107916.
  272. Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov;88:106903. [CrossRef]
  273. Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet Lond Engl. 2020;395(10238):1695–704. [CrossRef]
  274. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1365–76. [CrossRef]
  275. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497–511. [CrossRef]
  276. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Feb 16;325(7):632–44.
  277. Dougan M, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, et al. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clin Infect Dis. 2022 Jul 1;75(1):e440–9. [CrossRef]
  278. Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants [Internet]. bioRxiv; 2022 [cited 2023 Mar 2]. p. 2021.04.30.442182. Available from: https://www.biorxiv.org/content/10.1101/2021.04.30.442182v6.
  279. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1236–46. [CrossRef]
  280. Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. JAMA. 2022 Jan 25;327(4):384–5. [CrossRef]
  281. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021 Nov;27(11):2012–24. [CrossRef]
  282. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet. 2021 May 29;397(10289):2049–59. [CrossRef]
  283. Writing Committee for the REMAP-CAP Investigators. Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690–702.
  284. Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023 Jan;4(1):96–107. [CrossRef]
  285. Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023 Jan 12;6(1):e2250647. [CrossRef]
  286. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330–41. [CrossRef]
  287. Li H, Yan B, Gao R, Ren J, Yang J. Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. Int Immunopharmacol. 2021 Nov;100:108121. [CrossRef]
  288. Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022 Jul 14;60(1):2102532. [CrossRef]
  289. Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Lond Engl. 2021 Sep 4;398(10303):843–55. [CrossRef]
  290. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Jul;9(7):763–72. [CrossRef]
  291. Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul W, Koster DJ, et al. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA Intern Med. 2022 Jan 1;182(1):42–9. [CrossRef]
  292. Ezer N, Belga S, Daneman N, Chan A, Smith BM, Daniels SA, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ. 2021 Nov 2;375:e068060. [CrossRef]
  293. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Jul 28;71(15):769–77. [CrossRef]
  294. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020 Mar 28;395(10229):1054–62.
  295. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021 May 1;397(10285):1637–45. [CrossRef]
  296. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491–502. [CrossRef]
  297. Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 May;9(5):522–32. [CrossRef]
  298. Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014 Aug 15;462(1):1–13. [CrossRef]
  299. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol Orlando Fla. 2020 May;214:108393. [CrossRef]
  300. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet Lond Engl. 2020 Feb 15;395(10223):e30–1. [CrossRef]
  301. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet Lond Engl. 2022 Jul 30;400(10349):359–68.
  302. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1407–18. [CrossRef]
  303. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795–807. [CrossRef]
  304. Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 Sep;10(9):888–99. [CrossRef]
  305. Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Apr;10(4):327–36. [CrossRef]
  306. Jimenez D, Rali P, Doerschug K. COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. CHEST. 2022 Jun 1;161(6):1448–51. [CrossRef]
  307. Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet Lond Engl. 2021 Jun 12;397(10291):2253–63. [CrossRef]
  308. Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375:n2400. [CrossRef]
  309. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 Dec 1;181(12):1612–20. [CrossRef]
  310. Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, et al. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Jan 18;327(3):227–36. [CrossRef]
  311. Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021 Aug;9(8):924–32. [CrossRef]
  312. Mw M, S N, Dr B, Cj L, Tg S, Gm F, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2023 Jan 1;329(4):296–305. [CrossRef]
  313. Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. JAMA Netw Open. 2021 Feb 1;4(2):e210369. [CrossRef]
  314. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854–87. [CrossRef]
  315. Chu DK, Kim LHY, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet Lond Engl. 2018 Apr 28;391(10131):1693–705. [CrossRef]
  316. Barrot L, Asfar P, Mauny F, Winiszewski H, Montini F, Badie J, et al. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med. 2020 Mar 12;382(11):999–1008. [CrossRef]
  317. Valbuena VSM, Seelye S, Sjoding MW, Valley TS, Dickson RP, Gay SE, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. The BMJ. 2022 Jul 6;378:e069775. [CrossRef]
  318. Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May;195(9):1207–15. [CrossRef]
  319. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185–96. [CrossRef]
  320. Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med. 2018 Feb;36(2):226–33. [CrossRef]
  321. Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021 Dec 7;326(21):2161–71. [CrossRef]
  322. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PloS One. 2012;7(4):e35797. [CrossRef]
  323. Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021 May 4;325(17):1731–43. [CrossRef]
  324. Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):546–58. [CrossRef]
  325. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159–68. [CrossRef]
  326. Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. 2020 Mar 18;10:33. [CrossRef]
  327. Sartini C, Tresoldi M, Scarpellini P, Tettamanti A, Carcò F, Landoni G, et al. Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit. JAMA. 2020 Jun 9;323(22):2338–40. [CrossRef]
  328. Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021 Dec;9(12):1387–95. [CrossRef]
  329. Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, et al. Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2017 Oct;14(Supplement_4):S280–8. [CrossRef]
  330. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010 Mar 3;303(9):865–73.
  331. Tsolaki V, Siempos I, Magira E, Kokkoris S, Zakynthinos GE, Zakynthinos S. PEEP levels in COVID-19 pneumonia. Crit Care Lond Engl. 2020 Jun 6;24(1):303. [CrossRef]
  332. Schmidt M, Tachon G, Devilliers C, Muller G, Hekimian G, Bréchot N, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med. 2013 May;39(5):838–46. [CrossRef]
  333. Makdisi G, Wang I wen. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015 Jul;7(7):E166–76.
  334. Pham T, Combes A, Rozé H, Chevret S, Mercat A, Roch A, et al. Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2013 Feb 1;187(3):276–85.
  335. Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018 May 24;378(21):1965–75. [CrossRef]
  336. Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021 Jun;9(6):e002630. [CrossRef]
  337. Stainer A, Amati F, Suigo G, Simonetta E, Gramegna A, Voza A, et al. COVID-19 in Immunocompromised Patients: A Systematic Review. Semin Respir Crit Care Med. 2021 Dec;42(6):839–58. [CrossRef]
  338. Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023 May;59:101965. [CrossRef]
  339. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641–7.
  340. Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2021 Apr 1;137(4):571–80.
  341. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.
  342. Smith ER, Oakley E, Grandner GW, Rukundo G, Farooq F, Ferguson K, et al. Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period: a sequential, prospective meta-analysis. Am J Obstet Gynecol. 2023 Feb;228(2):161–77. [CrossRef]
  343. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, Sandoval-Mandujano K, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2021 Feb;57(2):224–31. [CrossRef]
  344. Molina RL, Tsai TC, Dai D, Soto M, Rosenthal N, Orav EJ, et al. Comparison of Pregnancy and Birth Outcomes Before vs During the COVID-19 Pandemic. JAMA Netw Open. 2022 Aug 12;5(8):e2226531. [CrossRef]
  345. Hecht JL, Quade B, Deshpande V, Mino-Kenudson M, Ting DT, Desai N, et al. SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Mod Pathol Off J U S Can Acad Pathol Inc. 2020 Nov;33(11):2092–103.
  346. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022 Jan;226(1):68-89.e3.
  347. Shah PS, Ye XY, Yang J, Campitelli MA. Preterm birth and stillbirth rates during the COVID-19 pandemic: a population-based cohort study. CMAJ. 2021 Aug 3;193(30):E1164–72. [CrossRef]
  348. DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640–5. [CrossRef]
  349. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. J Acquir Immune Defic Syndr 1999. 2020 Sep 1;85(1):6–10. [CrossRef]
  350. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 May 14;ciaa579. [CrossRef]
  351. Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021 Oct 5;73(7):e1964–72. [CrossRef]
  352. Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021 Nov;8(11):e690–700. [CrossRef]
  353. COVID-19 Treatment Guidelines [Internet]. [cited 2023 Jun 3]. HIV. Available from: https://www.covid19treatmentguidelines.nih.gov/special-populations/hiv/.
  354. Beaglehole B, Mulder RT, Frampton CM, Boden JM, Newton-Howes G, Bell CJ. Psychological distress and psychiatric disorder after natural disasters: systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2018 Dec;213(6):716–22. [CrossRef]
  355. Chaves C, Castellanos T, Abrams M, Vazquez C. The impact of economic recessions on depression and individual and social well-being: the case of Spain (2006-2013). Soc Psychiatry Psychiatr Epidemiol. 2018 Sep;53(9):977–86. [CrossRef]
  356. Hossain MM, Tasnim S, Sultana A, Faizah F, Mazumder H, Zou L, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Research. 2020 Jun 23;9:636. [CrossRef]
  357. Lu W, Wang H, Lin Y, Li L. Psychological status of medical workforce during the COVID-19 pandemic: A cross-sectional study. Psychiatry Res. 2020 Jun;288:112936. [CrossRef]
  358. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022 Feb 16;376:e068993. [CrossRef]
  359. Tessler H, Choi M, Kao G. The Anxiety of Being Asian American: Hate Crimes and Negative Biases During the COVID-19 Pandemic. Am J Crim Justice. 2020;45(4):636–46. [CrossRef]
  360. Grover S, Sahoo S, Mehra A, Avasthi A, Tripathi A, Subramanyan A, et al. Psychological impact of COVID-19 lockdown: An online survey from India. Indian J Psychiatry. 2020;62(4):354–62. [CrossRef]
  361. Chippa V, Aleem A, Anjum F. Post Acute Coronavirus (COVID-19) Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK570608/.
  362. Yong, SJ. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis Lond Engl. 2021 Oct;53(10):737–54. [CrossRef]
  363. Pintos-Pascual I, Moreno-Torres V, Ibánez-Estéllez F, Corrales-Rodriguez P, Treviño A, Corpas M, et al. Is SARS-CoV-2 the only cause of long-COVID? AIDS Rev. 2022 Dec 28;24(4):183–96. [CrossRef]
  364. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep;114(9):428–42. [CrossRef]
  365. Tosato M, Carfì A, Martis I, Pais C, Ciciarello F, Rota E, et al. Prevalence and Predictors of Persistence of COVID-19 Symptoms in Older Adults: A Single-Center Study. J Am Med Dir Assoc. 2021 Sep;22(9):1840–4. [CrossRef]
  366. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J Pediatr. 2022 Apr;181(4):1597–607.
  367. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol. 2021;12:686029. [CrossRef]
  368. Yao XH, He ZC, Li TY, Zhang HR, Wang Y, Mou H, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020 Jun;30(6):541–3. [CrossRef]
  369. Wang J, Mei F, Bai L, Zhou S, Liu D, Yao L, et al. Serum nitrite and nitrate: A potential biomarker for post-covid-19 complications? Free Radic Biol Med. 2021 Nov 1;175:216–25.
  370. Ahmad MS, Shaik RA, Ahmad RK, Yusuf M, Khan M, Almutairi AB, et al. “LONG COVID”: an insight. Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5561–77. [CrossRef]
  371. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis - PubMed [Internet]. [cited 2023 Jun 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/33532785/.
  372. Rao S, Benzouak T, Gunpat S, Burns RJ, Tahir TA, Jolles S, et al. Fatigue Symptoms Associated With COVID-19 in Convalescent or Recovered COVID-19 Patients; a Systematic Review and Meta-Analysis. Ann Behav Med Publ Soc Behav Med. 2022 Mar 1;56(3):219–34. [CrossRef]
  373. Ali SS, Mumtaz A, Qamar MA, Tebha SS, Parhin A, Butt M, et al. New-onset Parkinsonism as a Covid-19 infection sequela: A systematic review and meta-analysis. Ann Med Surg 2012. 2022 Aug;80:104281. [CrossRef]
  374. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021;177(1–2):51–64. [CrossRef]
  375. Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023 Jan;28(1):423–33. [CrossRef]
  376. Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A, et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021 Apr 18;13(4):700.
  377. Joshee S, Vatti N, Chang C. Long-Term Effects of COVID-19. Mayo Clin Proc. 2022 Mar;97(3):579–99. [CrossRef]
  378. Pulmonary long-term consequences of COVID-19 infections after hospital discharge - PMC [Internet]. [cited 2023 Jun 2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920814/.
  379. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021 Dec;49(6):1163–86. [CrossRef]
  380. Chaudhry ZS, Nellessen N, Reis C, Sharip A. The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 2022 Nov 22;39(6):1116–34. [CrossRef]
  381. Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal Consequences of COVID-19. J Bone Joint Surg Am. 2020 Jul 15;102(14):1197–204. [CrossRef]
  382. Koutalos AA, Stefanou N, Malizos KN. Postacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2022 Aug;121:11–3. [CrossRef]
  383. Kordyukova LV, Shanko AV. COVID-19: Myths and Reality. Biochem Biokhimiia. 2021;86(7):800–17. [CrossRef]
  384. Poutoglidou F, Saitis A, Kouvelas D. Ibuprofen and COVID-19 disease: separating the myths from facts. Expert Rev Respir Med. 2021 Aug;15(8):979–83. [CrossRef]
  385. Tang JW, Bahnfleth WP, Bluyssen PM, Buonanno G, Jimenez JL, Kurnitski J, et al. Dismantling myths on the airborne transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Hosp Infect. 2021 Apr;110:89–96.
  386. Sahoo S, Padhy SK, Ipsita J, Mehra A, Grover S. Demystifying the myths about COVID-19 infection and its societal importance. Asian J Psychiatry. 2020 Dec;54:102244. [CrossRef]
  387. Challenger A, Sumner P, Bott L. COVID-19 myth-busting: an experimental study. BMC Public Health. 2022 Jan 19;22(1):131. [CrossRef]
  388. Roy, S. Roy S. COVID-19 Reinfection: Myth or Truth? SN Compr Clin Med. 2020;2(6):710–3.
  389. Fowler AA III, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019 Oct 1;322(13):1261–70.
  390. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020 Aug;54(8):820–6. [CrossRef]
  391. Kumar S, Sil A, Das A. Hydroxychloroquine for COVID-19: Myths vs facts. Dermatol Ther. 2020;33(6):e13857.
  392. Al-Bari, AA. Al-Bari AA. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. Curr Drug Targets. 2020;21(16):1703–21. [CrossRef]
  393. Mercurio AM, Gianakos AL, Mulcahey MK, Sutton KM. Five Myths of COVID-19 for the Team Physician. HSS J Musculoskelet J Hosp Spec Surg. 2020 Nov;16(Suppl 1):173–8. [CrossRef]
Preprints 78925 g001
Figure 1. Timeline of detection of Coronaviruses.
Figure 1. Timeline of detection of Coronaviruses.
Preprints 78925 g001
Preprints 78925 g002
Figure 2. Timeline of SARS-CoV-2 Variants of Concern.
Figure 2. Timeline of SARS-CoV-2 Variants of Concern.
Preprints 78925 g002
Preprints 78925 g003
Figure 3. Structure of SARS-CoV-2 Scientific Animations (CC BY-SA 4.0).
Figure 3. Structure of SARS-CoV-2 Scientific Animations (CC BY-SA 4.0).
Preprints 78925 g003
Preprints 78925 g004
Figure 4. Different phases of COVID-19 progression.
Figure 4. Different phases of COVID-19 progression.
Preprints 78925 g004
Preprints 78925 g005
Figure 5. Histological changes from COVID-19 in lungs. (A) Alveolar injury with desquamation and hyaline membrane formation (arrow). (B) No evidence of inflammatory cellular infiltration. (C) Interstitial thickening. (D) Intra-alveolar hemorrhages (asterisk) and the presence of fibrin plugs. (E) Interstitial thickening due to ACT2 hyperplasia and alveolar infiltration by inflammatory cells with fibrinoid necrosis noted. (F) Intra-alveolar infiltration with neutrophils suggestive of bacterial superinfection. (Courtesy: Tian, S., Xiong, Y., Liu, H., et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol (2020)).
Figure 5. Histological changes from COVID-19 in lungs. (A) Alveolar injury with desquamation and hyaline membrane formation (arrow). (B) No evidence of inflammatory cellular infiltration. (C) Interstitial thickening. (D) Intra-alveolar hemorrhages (asterisk) and the presence of fibrin plugs. (E) Interstitial thickening due to ACT2 hyperplasia and alveolar infiltration by inflammatory cells with fibrinoid necrosis noted. (F) Intra-alveolar infiltration with neutrophils suggestive of bacterial superinfection. (Courtesy: Tian, S., Xiong, Y., Liu, H., et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol (2020)).
Preprints 78925 g005
Preprints 78925 g006
Figure 6. Organ system manifestations of COVID-19.
Figure 6. Organ system manifestations of COVID-19.
Preprints 78925 g006
Preprints 78925 g007
Figure 7. List of various types of COVID-19 trials.
Figure 7. List of various types of COVID-19 trials.
Preprints 78925 g007
Preprints 78925 g008
Figure 8. Different Types of Vaccine Platforms (Image Courtesy: covid19.trackvaccine.org).
Figure 8. Different Types of Vaccine Platforms (Image Courtesy: covid19.trackvaccine.org).
Preprints 78925 g008
Table 1. The list of variants of SARS-CoV-2.
Table 1. The list of variants of SARS-CoV-2.
WHO Nomenclature Lineage Emergence
Alpha B.1.1.7 Great Britain
Beta B.1.351 South Africa
Delta B.1.617.2 India
Gamma P.1 Brazil
Epsilon B.1.427 USA
Eta B.1.525 USA
Iota B.1.526 USA
Kappa B.1.617.1 India
Mu B.1.621 Columbia
Zeta P.2 Brazil
Omicron B.1.1.529 South Africa
Table 2. List of COVID-19 trials.
Table 2. List of COVID-19 trials.
Treatments
Study/Year Treatment
(Interventions)		 Study Design Stratification Methods No of Participants (n) Outcomes Limitations Other events/observations
COVID-19 Convalescent Plasma - September 2020 Convalescent Plasma FDA-initiated, national, multicenter, open-label to evaluate the safety of convalescent plasma for patients at high risk of progression to) severe or life-threatening COVID Open-label 20,000 Convalescent plasma was safe and likely to reduce mortality Convalescent plasma therapy had to be given early in the course of the disease Subsequent trials found no consistent evidence of benefit
RECOVERY (236) - October 2020 Lopinavir 400 mg plus ritonavir 100 mg by mouth every 12 h for 10 days or until
discharge		 Randomized controlled, Open-label 2:1:1 Standard of care alone or usual standard of care plus lopinavir–ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin 1616 Lopinavir–ritonavir was not effective Open-label, very few patients on ventilator were enrolled It is unclear whether the dose of lopinavir–ritonavir we used achieved adequate SARS-CoV-2 inhibitory concentrations in the lungs
Remdesivir - ACTT-1 (237) - November 2020 Remdesivir vs placebo Double-blind, randomized, placebo-controlled trial 1:1 ratio to receive Remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to
9 additional days) or placebo for up to 10 days.		 1062 Remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with COVID-19 Data on 4.8% of the study were unblinded to provide data to the sponsor, Study had a crossover during this early phase of COVID. The primary outcome of the current trial was changed early in the trial, from a comparison of outcomes on day 15 to a comparison of time to recovery up to day 29.
Coalition I (238) - November 2020 Hydroxychloroquine, azithromycin or standard of care Open-label three group RCT Randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin for 7 days for Mild-to-Moderate COVID-19 667 Did not improve clinical status at 15 days Could not rule out either a substantial benefit or substantial harm. Other trials did not show benefit for post-exposure prophylaxis in mild COVID

SOLIDARITY trial (239) - January 2021		 Remdesivir, lopinavir/ritonavir combined with interferon-beta, and hydroxychloroquine or chloroquine. Open-label phase III-IV clinical trial organized by the World Health Organization (WHO), Participants were randomly allocated to get one of the 4 therapies Random assignment to receive one of the 4 treatments 14,304 Hospitalized patients with COVID-19 treated with remdesivir had lower death rates and reduced need for oxygen, but no difference in patients already on mechanical ventilation Trial period had outbreaks due to different strains, delta,
and omicron variants. Vaccinations also became more widespread during the trial. Mechanical ventilators were available in resource-limited countries.		 WHO suspended the hydroxychloroquine arm of the Solidarity trial in late May 2020
RECOVERY (240) - February 2021 Usual standard of care alone or the usual standard of care plus oral or
intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or until hospital
discharge		 Randomized controlled, Open-label 2:1 ratio randomization to receive usual care alone or usual standard of care plus oral or
intravenous dexamethasone		 2104 Lower 28-day mortality among those on invasive mechanical
ventilation or oxygen		 Open-label, the standard of care varied during the trial period Patients in the dexamethasone group had a
shorter duration of hospitalization than those in
the usual care group
INSPIRATION (241) - March 2021 Intermediate vs standard prophylactic dose Enoxaparin RCT, 10 academic centers in Iran Intermediate-dose (enoxaparin, 1 mg/kg daily) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until the completion of the 30-day follow-up. 600 No differences in venous or arterial thrombus, treatment with ECMO or mortality within 30 days Open-label, enrolled ICU patients but not severely ill patients requiring ECMO, lack of systematic screening for venous thromboembolism, only 4 patients were >120kg increased risk of bleeding (2.5%) in intermediate dose group which did not meet non -inferiority criteria, severe thrombocytopenia only occurred in intermediate dose group.
COVACTA (242) - May 2021 Standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg Open-label 21,550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab 4116 Tocilizumab improved survival Duration of hospitalization beyond 28 days was not recorded 16% of patients in the tocilizumab group did not receive this treatment and the reasons for this were not recorded
Heparin (243) - August 2021 Therapeutic-dose anticoagulation with heparin vs pharmaco-
logic thromboprophylaxis		 Open-label RCT, critically ill
patients with severe COVID-19		 1:1 randomization to therapeutic-dose anticoagulation with heparin vs pharmaco- logic thromboprophylaxis in accordance with local usual care 1098 No differences in of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support Open-label, most patients were from the United Kingdom, practice guideline changed during the trial period and majority received intermediate dose anticoagulation in the control group Incidence of major bleeding was 3.8% in the treatment group
ECMO (244) - September 2021 Outcomes after ECMO in COVID Analysis of the Extracorporeal Life Support Organization Registry and COVID-19 for between group comparison of ECMO-supported patients with COVID-19 Retrospective analysis of ECMO registries 4812 Mortality for ECMO-supported patients
with COVID-19 worsened worldwide over the course of the pandemic, and duration of ECMO support increased.		 Not an RCT, did not give insight about which patients need ECMO support Mortality ranged between 38 to 59%
Remdesivir plus standard of care - DISCOVERY (245) - September 2021 Remdesivir plus standard of care Phase 3, open-label, adaptive, multicenter, randomized, controlled trial conducted in
48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg), between March 22, 2020, and Jan 21, 2021,		 1:1 randomization, Remdesivir was administered intravenously at a loading
dose of 200 mg on day 1 followed by a 100 mg, for a total duration of 10 days. Its
cessation was allowed after 5 days if the participant was discharged from the hospital.		 857 No clinical benefit was observed from the use of remdesivir in symptomatic patients for more than 7 days and required oxygen support. Open-label, several treatments were concomitantly evaluated during the trial period, no viral load assessment was available at any time point Among the subset of participants without mechanical ventilation or ECMO at randomization, remdesivir significantly delayed the need for new mechanical ventilation or ECMO, or death, consistent with what was reported in ACTT-1.9
Aspirin- RECOVERY (246) - November 2021 Aspirin Open-label RCT, 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal, Nov 1, 2020, and March 21, 2021 1:1 ratio to either the usual standard of care plus 150 mg aspirin once per day until discharge or the usual standard of care alone 14892 No reduction in 28-day mortality, mechanical ventilation, or death, a small increase of 1 median day of being discharged alive. Open-label, only hospitalized patients were studied, radiological information was not collected, The effects of Aspirin were like other trials of patients with cardiovascular disease
COVID-PRONE (247) - January 2022 Proning in patient requiring up to 50% fraction of
inspired oxygen but not critically ill		 Randomized 1:1 to prone positioning Patients were randomized 1:1 to prone positioning
(That is, instructing a patient to lie on their stomach
while they are in bed) or standard of care		 570 Prone positioning did not improve outcomes in hospitalized hypoxemic patients Adherence to prone positioning was poor, despite multiple efforts to increase it, time spent prone was self-reported and thus at risk of recall bias, The median total time spent in prone position
up to the first 72 hours was 6 hours
CPAP - RECOVERY-RS (248) - January 2022 CPAP vs conventional oxygen Parallel group, adaptive, randomized clinical trial from April 6, 2020, and May 3, 2021, across 48 acute care hospitals in the UK and Jersey 1:1 randomization 1273 Initial strategy of CPAP significantly reduced the risk of tracheal intubation or mortality compared with conventional oxygen therapy Cross over occurred Treatment crossover occurred in 17.1% of participants.
Early treatment with Ivermectin (249) - March 2022 Ivermectin Double-blind, randomized, placebo-controlled, adaptive platform
trial, 12 public health clinics in Brazil.		 Patients were randomized to receive ivermectin (679 patients), placebo (679), or another intervention (2157)., ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo. 3515 Did not result in a lower incidence of medical admission to a hospital due to the progression of disease among outpatients with an early diagnosis of COVID-19. Enrolled patients only in Brazil, although 3515 patients were enrolled, ivermectin vs placebo was compared only in 679 patients There was no evidence of a treatment effect with ivermectin as compared with placebo in subgroups defined according to patient age, body-mass index, status of having cardiovascular disease or lung disease, sex, smoking status, or time since symptom onset
Colchicine and Rivaroxaban- Anti-Coronavirus Therapies (ACT) Trial (250) - October 2022 Colchicine and Rivaroxaban + Aspirin Open-label RCT, 62 clinical centers in 11 countries between Oct 2, 2020, and Feb 10, 2022 colchicine 1·2 mg followed by 0·6 mg 2 h later within 72 hours of hospitalization and then 0·6 mg twice daily for 28 days versus usual care; and in a second (1:1) randomization, to the combination of rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days versus usual care 2749 No prevention of disease progression or death Open-label, the trial was done over 18 months and different therapies were used, different strains emerged, vaccinations increased as the trial progressed 56 to 65% of patients were unvaccinated.
Nirmatrelvir and Ritonavir EPIC-HR (251) - February 2022 300 mg of nirmatrelvir plus 100 mg of ritonavir vs placebo Phase 2–3 double-blind, randomized, controlled trial 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir for 5 days 2246 The risk of progression to severe COVID-19 was 89% lower than the risk with a placebo The median age was only 45 years and the predominantly white population The trial was restricted to unvaccinated
persons
Long-term cardiovascular outcomes of COVID-19 (252) - March 2022 Prospective cohort Data was reported from the US Department of Veterans Affairs
national healthcare databases		 The healthcare database was used to build a cohort and then followed longitudinally to estimate the risks and 12-month burdens of pre-specified incident cardiovascular outcomes 153,760 risk and 12-month burden of ischemic and non-ischemic heart disease, dysrhythmias increased post COVID Majority were males Increased risk of myocarditis and pericarditis reported in this study is significant in people who were not vaccinated and is evident
regardless of vaccination status.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19
- REMAP-CAP (253) - December 2022		 Follow-up study Randomized to receive 1 or more interventions within 6 treatment domains: immune modulators, convalescent plasma, antiplatelet therapy (n = 1557), anticoagulation, antivirals, and corticosteroids 4869 IL-6 receptor antagonist had a
greater than 99.9% probability of improved 180-day mortality		 Open-label, not all centers collected quality of life and disability scores 1 in 3 patients had at least moderate disability that persisted through 6 months
Nirmatrelvir–ritonavir (254) - February 2023 nirmatrelvir–ritonavir for reducing hospital
admissions and mortality from COVID-19		 Population-based cohort study Population-based follow-up study 177,545 Significantly reduced odds of hospital admission and death from COVID-19, Study tracked prescriptions, could not confirm adherence Number needed to treat= 62.
Prevention
Phase 3 of BLAZE-1 trial, Bamlanivimab plus Etesevimab (255) - July 2021 2800 mg of Bamlanivimab and 2800 mg of Etesevimab within 3 days of in Mild or Moderate COVID-19 Double-blind, placebo-controlled, RCT, single-dose trial conducted in the United States Ambulatory patients with mild or moderate COVID-19, who were at high risk for progression to severe disease were randomized in a 1:1 ratio to receive a single intravenous infusion of either a neutralizing
monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis. The primary outcome was the overall clinical status of the patients, defined as COVID-19–related hospitalization or death from any cause by day 29.		 1035 Bamlanivimab plus etesevimab resulted in more rapid resolution of symptoms within 4 days after the initiation of treatment, less hospitalization and death compared to placebo, and accelerated decline in the SARS-CoV-2 viral load. 12.6% were whites, conduction only in the United States with very few adolescents, emergency use authorization for bamlanivimab plus etesevimab is for administration within 10 days but was administered within 3 days in the study On 16 April 2021, the FDA revoked the emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab to be used alone
REGEN-COV (256) - September 2021 combination of the monoclonal antibodies casirivimab and imdevimab, REGEN-COV 2400-mg vs placebo Phase 3, randomized controlled trial 1:1:1 ratio
to receive intravenous REGEN-COV at a dose of

2400 mg (1200 mg each of casirivimab and im-
devimab) or 8000 mg (4000 mg of each anti-
body) or intravenous placebo		 2696 REGEN-COV reduced the risk of COVID-19–related hospitalization or death from any Efficacy against other strains was not studied FDA has revised the EUAs for Bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) and are currently not authorized for use due to inactivity against the omicron variant
Vaccines
Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine(Pfizer) (257) - December 2020 BNT162b2 mRNA vaccine vs placebo Randomized placebo-controlled, observer-blinded 1:1 ratio to receive
two doses, 21 days apart, of either placebo or the BNT162b2 vaccine		 43,548 cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rap- The endpoints in protocols for different vaccines are different, difficult to compare efficacy across different vaccine groups Further studies showed that the bivalent vaccine was 58.7% effective against hospitalization compared to 25% for the monovalent one that preceded it
Astrazeneca COVID vaccine AZD1222 against SARS-CoV-2 (258) January 2021 ChAdOx1 nCoV-19 vaccine (AZD1222) Randomized, blinded, controlled trials done across three countries: COV001 (phase 1/2; UK), COV002 (phase 2/3; UK), COV003 (phase 3; Brazil), and COV005 (phase 1/2; South Africa) between April 23 and Nov 4, 2020 Two standard doses vs one low dose followed by standard dose 23,848 idly than placebo. The endpoints in protocols for different vaccines are different, difficult to compare efficacy across different vaccine groups
Efficacy and Safety of the mRNA-1273 Vaccine (Moderna) (259) - February 2021 mRNA-1273 vaccine vs placebo Phase 3 randomized, observer-blinded, placebo-controlled trial 1:1 ratio to receive two intra-
muscular injections of mRNA-1273 (100 μg) or a placebo 28 days apart.		 30,420 94.1% efficacy at preventing COVID-19 illness,
including severe disease		 The endpoints in protocols for different vaccines are different, difficult to compare efficacy across different vaccine groups Further studies showed effectiveness against the XBB strains varied by age: in ages 18 to 49, it was 49% against the XBB strains versus 52% against the BA.5 viruses; in ages 50 to 64, it was 40% compared to 43% for BA.5; and in people 65 and older, 43%, compared to 37% for the BA.5 viruses.
ENSEMBLE trial-Johnson and Johnson vaccine (260) - April 2021 Ad26.COV2.S vaccine against COVID-19 Randomized, double-blinded, placebo-controlled trial 1:1 ratio to receive a single dose of
Ad26.COV2.S (5×1010 viral particles) or placebo.		 39,321 Safety appeared to be similar to that in other phase 3 trials of COVID-19 vaccines. The endpoints in protocols for different vaccines are different, difficult to compare efficacy across different vaccine groups
Efficacy and Safety of NVX-CoV2373 (Novavax) (261) - February 2022 NVX-CoV2373 vaccine vs placebo Phase 3, randomized, observer-blinded, placebo-controlled trial at 113 clinical sites 2:1 ratio to receive two doses of NVX-CoV2373 or placebo 21 days apart 29,949 Two doses of NVX-CoV2373 were safe The endpoints in protocols for different vaccines are different, difficult to compare efficacy across different vaccine groups Had a blinded crossover approximately 3 to 4 months after the first vaccination series to allow all trial participants to receive NVX-CoV2373, after vaccine efficacy and required safety had been established and reviewed
COVID and risk of incident diabetes (262) - December 2022 COVID vaccine Self-controlled crossover observational cohort, Cedars-Sinai Health System in Los Angeles, California from March 2020 to June 2022 23,709 The risk of type 2 diabetes after COVID infection was higher in unvaccinated individuals compared to vaccinated individuals
Ongoing trials
COVERAGE-A Early Treatment of Vulnerable Individuals with Non-Severe SARS-CoV-2 Infection - Full - Text View - ClinicalTrials.gov Early treatment of vulnerable individuals with non-severe SARS-CoV-2
SOLIDARITY PLUS SOLIDARITY Finland Plus Long-COVID - Full Text View - ClinicalTrials.gov Enroll hospitalized patients to test artesunate, imatinib and infliximab.
HALT-COVID-19 Inhalation of Ciclesonide for Patients With COVID-19: A Randomized Open Treatment Study (HALT COVID-19) - No Study Results Posted - ClinicalTrials.gov Inhaled Ciclesonide


Table 3. Medications used to date in the treatment of COVID-19 infection.
Table 3. Medications used to date in the treatment of COVID-19 infection.
Preprints 78925 i001
Table 4. COVID-19 vaccines approved by WHO under EUL.
Table 4. COVID-19 vaccines approved by WHO under EUL.
Vaccine Vaccine Type Vaccine Platform Approved Countries No of Trials WHO EUL recommendation Age indication Shelf life EUL Holder Approval Source Trials Link
COVOVAX SARS-CoV-2 rS Protein Nanoparticle [Recombinant] Protein subunit 6 7 17 December 2021 12 years and older 9 months Storage temperature: 2°C to 8°C Serum Institute of India Pvt. Ltd. (SIIPL) COVOVAX | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines, and Immunization Devices, Vector Control) Serum Institute of India: COVOVAX (Novavax formulation) – COVID19 Vaccine Tracker
NOVAVAX SARS-CoV-2 rS [Recombinant, adjuvanted] Protein subunit 40 22 20 December 2021 12 years and older 9 months Storage temperature: 2°C to 8°C Serum Institute of India Pvt. Ltd. (SIIPL) NUVAXOVID | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines, and Immunization Devices, Vector Control) Novavax: Nuvaxovid – COVID19 Vaccine Tracker
MODERNA COVID-19 mRNA Vaccine (nucleoside modified) RNA 88 70 30 April 2021 6 years and older 9 months Storage temperature: -20°C ± 5°C Moderna Biotech COVID-19 mRNA Vaccine (nucleoside modified) Moderna: Spikevax – COVID19 Vaccine Tracker
Pfizer/BioNTech COVID-19 mRNA vaccine (nucleoside modified) RNA 149 100 31 December 2020 6 months and older 9 months Storage temperature: - 90°C to - 60°C BioNTech Manufacturing GmbH WHO recommendation BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY Pfizer/BioNTech: Comirnaty – COVID19 Vaccine Tracker
CanSino Ad5-nCoV-S [Recombinant] Non-Replicating Viral Vector 10 14 19 May 2022 18 to 59 years of age 12 months Storage temperature: 2°C to 8°C CanSino Biologics Inc. CONVIDECIA | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) CanSino: Convidecia – COVID19 Vaccine Tracker
Janssen Ad26.COV2-S [recombinant] Non-Replicating Viral Vector 113 26 12 March 2021 18 years and older 24 months Storage temperature: -25°C to -15°C Janssen–Cilag International NV COVID-19 Vaccine (Ad26.COV2-S [recombinant]) Janssen (Johnson & Johnson): Jcovden – COVID19 Vaccine Tracker
Oxford/AstraZeneca ChAdOx1-S ([recombinant] Non-Replicating Viral Vector 149 73 15 February 2021 18 years and older 6 months Storage temperature: 2°C to 8°C AstraZeneca/SK Bioscience Co. Ltd WHO Recommendation AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant]) Oxford/AstraZeneca: Vaxzevria – COVID19 Vaccine Tracker
Covishield ChAdOx1-S ([recombinant] Non-Replicating Viral Vector 49 6 15 February 2021 18 years and older 9 months Storage temperature: 2°C to 8°C Serum Institute of India Pvt. Ltd COVISHIELD | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) Serum Institute of India: Covishield (Oxford/ AstraZeneca formulation) – COVID19 Vaccine Tracker
Covaxin Whole Virion Inactivated Corona Virus vaccine Inactivated 14 16 03 November 2021 18 years and older 9 months Storage temperature: 2°C to 8°C Bharat Biotech International Ltd. COVAXIN | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) Bharat Biotech: Covaxin – COVID19 Vaccine Tracker
SinoPharm COVID-19 Vaccine (Vero Cell), Inactivated Inactivated 93 39 07 May 2021 18 years and older 24 months Storage temperature: 2°C to 8° C Beijing Institute of Biological Products Co., Ltd. (BIBP) COVID-19 Vaccine (Vero Cell), Inactivated Sinopharm (Beijing): Covilo – COVID19 Vaccine Tracker
Sinovac COVID-19 Vaccine (Vero Cell), Inactivated Inactivated 56 42 01 June 2021 3 to 59 years of age 24 months Storage temperature: 2°C to 8° C Sinovac Life Sciences Co., Ltd. CoronaVac | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) Sinovac: CoronaVac – COVID19 Vaccine Tracker
Table 5. List of COVID-19 vaccines approved worldwide.
Table 5. List of COVID-19 vaccines approved worldwide.
Vaccine Approved countries Trials Links
Anhui Zhifei Longcom: Zifivax 4 21 https://covid19.trackvaccines.org/vaccines/27/
Bagheiat-allah University of Medical Sciences: Noora vaccine 1 3 https://covid19.trackvaccines.org/vaccines/129/
Bharat Biotech: Covaxin 14 16 https://covid19.trackvaccines.org/vaccines/9/
Bharat Biotech: iNCOVACC 1 4 https://covid19.trackvaccines.org/vaccines/87/
Biological E Limited: Corbevax 2 7 https://covid19.trackvaccines.org/vaccines/54/
CanSino: Convidecia 10 14 https://covid19.trackvaccines.org/vaccines/2/
CanSino: Convidecia Air 2 5 https://covid19.trackvaccines.org/vaccines/162/
Center for Genetic Engineering and Biotechnology:Abdala 6 5 https://covid19.trackvaccines.org/vaccines/67/
Chumakov center: KoviVac 3 5 https://covid19.trackvaccines.org/vaccines/100/
Gamaleya: Gam-COVID-Vac 1 2 https://covid19.trackvaccines.org/vaccines/191/
Gamaleya : Sputnik light 26 7 https://covid19.trackvaccines.org/vaccines/126/
Gamaleya : Sputnik V 74 25 https://covid19.trackvaccines.org/vaccines/12/
Gennova Biopharmaceuticals Ltd: Gemcovac-16 1 2 https://covid19.trackvaccines.org/vaccines/200/
Health institutes of Turkey: Turkovac 1 8 https://covid19.trackvaccines.org/vaccines/77/
Instituto Finlay de Vacunas Cuba : Soberana 02 4 2 https://covid19.trackvaccines.org/vaccines/52/
Instituto Finlay de Vacunas Cuba : Soberana Plus 2 5 https://covid19.trackvaccines.org/vaccines/119/
Janssen (Johnson & Johnson) 113 26 https://covid19.trackvaccines. /vaccines/1/
Livzon Mabpharm Inc: V-01 1 7 https://covid19.trackvaccines.org/vaccines/108/
Medicago: Covifenz 1 6 https://covid19.trackvaccines.org/vaccines/26/
Medigen: MVC-COV1901 4 15 https://covid19.trackvaccines.org/vaccines/24/
Moderna: Spikevax 88 70 https://covid19.trackvaccines.org/vaccines/22/
Moderna: Spikevax Bivalent Original/Omicron BA.1 38 5 https://covid19.trackvaccines.org/vaccines/210/
Moderna: Spikevax Bivalent Original/Omicron BA.4/BA.5 33 2 https://covid19.trackvaccines.org/vaccines/224/
National Vaccine and Serum institute: Recombinant SARS-Cov-2 Vaccine(CHO cell) 1 3 https://covid19.trackvaccines.org/vaccines/114/
Novavax: Nuvaxovid 40 22 https://covid19.trackvaccines.org/vaccines/25/
Organization of Defensive innovation and research: FAKHRAVAC (MIVAC) 1 3 https://covid19.trackvaccines.org/vaccines/97/
Oxford/AstraZeneca: Vaxzevria 149 73 https://covid19.trackvaccines.org/vaccines/4/
Pfizer/BioNtech: Comirnaty 149 100 https://covid19.trackvaccines.org/vaccines/6/
Pfizer/BioNtech: Comirnaty Bivalent Original /Omicron BA.1 35 3 https://covid19.trackvaccines.org/vaccines/223/
Pfizer/BioNtech: Comirnaty Bivalent Original /Omicron BA.4/BA.5 33 4 https://covid19.trackvaccines.org/vaccines/225/
PT Bio Farma : IndoVac 1 4 https://covid19.trackvaccines.org/vaccines/187/
Razi Vaccine and Serum Research Institute : Razi Cov Pars 1 5 https://covid19.trackvaccines.org/vaccines/82/
Research Institute for Biological Safety Problems (RIBSP): QazVac 2 3 https://covid19.trackvaccines.org/vaccines/30/
Sanofi/GSK: VidPrevtyn Beta 30 3 https://covid19.trackvaccines.org/vaccines/165/
Serum Institute of India: Covishield(Oxford/AstraZeneca formulation) 49 6 https://covid19.trackvaccines.org/vaccines/48/
Serum Institute of India: Covovax ( Novavax formulation) 6 7 https://covid19.trackvaccines.org/vaccines/123/
Shenzhen Kangtai Biological Products Co: KCONVAC 2 7 https://covid19.trackvaccines.org/vaccines/47/
Shifa Pharmed Industrial Co: COVIran Barekat 1 6 https://covid19.trackvaccines.org/vaccines/83/
Sinopharm (Beijing) Covilo 93 39 https://covid19.trackvaccines.org/vaccines/5/
Sinopharm (Wuhan) : Inactivated (Vero cells) 2 9 https://covid19.trackvaccines.org/vaccines/16/
Sinovac : CoronaVac 56 42 https://covid19.trackvaccines.org/vaccines/7/
SK Bioscience Co Ltd : SKYCovione 1 7 https://covid19.trackvaccines.org/vaccines/81/
Takeda: TAK-019 (Novavax formulation) 1 3 https://covid19.trackvaccines.org/vaccines/80/
Takeda : TAK -919 (Moderna formulation) 1 2 https://covid19.trackvaccines.org/vaccines/79/
Valneva: VLA2001 33 9 https://covid19.trackvaccines.org/vaccines/69/
Vaxine/CinnaGen Co: SpikoGen 1 8 https://covid19.trackvaccines.org/vaccines/8/
Vector State Research center of Virology and biotechnology: Aurora -Cov 1 2 https://covid19.trackvaccines.org/vaccines/169/
Vector State Research center of Virology and biotechnology: EpiVacCorona 4 4 https://covid19.trackvaccines.org/vaccines/32/
WalVax: AWcorna 1 4 https://covid19.trackvaccines.org/vaccines/23/
Zydus Cadila: ZyCov-D 1 6 https://covid19.trackvaccines.org/vaccines/29/
Table 6. Long-COVID complications.
Table 6. Long-COVID complications.
System Long-COVID Complications
Neuropsychiatric (371–375) Chronic Fatigue syndrome
Headache
Myelitis
Neuropathies
Paresthesia
Parkinsonism
Cogwheel rigidity
Optic neuritis
Anosmia
Ageusia
Encephalitis
Epilepsy
Bell’s palsy
Myoclonus
Transient Ischemic Attack
Stroke
Depression
Anxiety

Pulmonary (151,376–379)		 Pulmonary fibrosis
Pulmonary thromboembolism
Acute Respiratory Distress Syndrome
Pulmonary embolism
Pneumothorax
Cardiovascular (12,13) Dysrhythmias
Atrial Fibrillation/flutter
Ventricular arrhythmias
Sinus tachycardia/bradycardia
Inflammatory heart disease
Pericarditis/myocarditis
Coronary artery disease
Cardiomyopathy (ischemic/nonischemic)
Endocrine (14)
 Fulminant type diabetes/autoimmune diabetes/ new-onset transient hyperglycemia
Rheumatology (380–382) Polyarthritis
Osteoporosis
Osteonecrosis
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated